Brain Scientific (BRSF) 10-K 15 Apr 21 2020 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Apr. 14, 2021	Jun. 30, 2020
Document Information Line Items
Entity Registrant Name	BRAIN SCIENTIFIC INC.
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		19,706,086
Entity Public Float			$ 16,211,681.80
Amendment Flag	false
Entity Central Index Key	0001662382
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	true
Entity File Number	333-209325
Entity Incorporation, State or Country Code	NV
Entity Interactive Data Current	Yes

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash	$ 272,856	$ 261,436
Accounts receivable, net	1,460	5,555
Inventory, net	1,461
Prepaid expenses and other current assets	93,807	21,637
Prepaid expenses and other current assets - related party	700	700
Operating lease right-of-use asset	69,632
TOTAL CURRENT ASSETS	439,916	289,328
Property and equipment, net	302	1,674
TOTAL ASSETS	440,218	291,002
CURRENT LIABILITIES:
Accounts payable and accrued expenses	994,908	298,578
Accounts payable and accrued expenses - related party	6,600	9,263
Notes payable, net	72,466	50,000
Convertible notes payable, net	1,192,804	499,232
Derivative liabilities	2,562,942
Finance lease - short term	4,595	6,377
Loans payable	6,667
Loans payable - related party	322,991	323,084
Operating lease liability, current portion	41,793
TOTAL CURRENT LIABILITIES:	5,205,766	1,186,534
Operating lease liability, net of current portion	31,276
TOTAL LIABILITIES	5,237,042	1,186,534
Commitments and contingencies
STOCKHOLDERS’ DEFICIT
Preferred stock, $0.001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively
Common stock, $0.001 par value; 200,000,000 shares authorized, 19,628,258 and 19,380,460 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively	19,628	19,381
Additional paid in capital	3,144,490	2,756,798
Accumulated deficit	(7,956,862)	(3,672,077)
Accumulated other comprehensive income (loss)	(4,080)	366
TOTAL STOCKHOLDERS’ DEFICIT	(4,796,824)	(895,532)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$ 440,218	$ 291,002

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	19,628,258	19,380,460
Common stock, shares outstanding	19,628,258	19,380,460

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
REVENUE	$ 544,275	$ 489,202
COST OF GOODS SOLD	409,302	387,194
GROSS PROFIT	134,973	102,008
SELLING, GENERAL AND ADMINISTRATIVE
Research and development	275,926	103,616
Professional fees	478,461	255,332
Sales and marketing expenses	244,774	95,165
Occupancy expenses	38,870	85,771
General and administrative expenses	930,138	532,312
TOTAL SELLING, GENERAL AND ADMINISTRATIVE	1,968,169	1,072,196
LOSS FROM OPERATIONS	(1,833,196)	(970,188)
OTHER INCOME (EXPENSE):
Interest expense	(3,526,325)	(32,922)
Other income	8,260	2,108
Other expense		(597)
Loss on debt extinguishment	(294,301)
Change in fair value of derivative liabilities	1,360,754
Foreign currency transaction loss	23	(52)
TOTAL OTHER EXPENSE	(2,451,589)	(31,463)
LOSS BEFORE INCOME TAXES	(4,284,785)	(1,001,651)
PROVISION FOR INCOME TAXES		(2,214)
NET LOSS	(4,284,785)	(1,003,865)
OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustment	(4,446)	366
TOTAL COMPREHENSIVE LOSS	$ (4,289,231)	$ (1,003,499)
NET LOSS PER COMMON SHARE
Basic and diluted (in Dollars per share)	$ (0.22)	$ (0.05)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
Basic and diluted (in Shares)	19,439,141	19,236,380

Consolidated Statements of Stoc

Consolidated Statements of Stockholders’ Deficit - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Total
Balances at Dec. 31, 2018	$ 19,206	$ 2,595,034	$ (2,668,212)		$ (53,972)
Balances (in Shares) at Dec. 31, 2018	19,205,624
Fair value of stock options vested		12,797			12,797
Fair value of warrants issued in connection with convertible debt		130,768			130,768
Capital contribution and write off of related party accounts payable		653			653
Issuance of common stock for services	$ 175	17,546			17,721
Issuance of common stock for services (in Shares)	174,836
Foreign currency translation adjustment				366	366
Net loss			(1,003,865)		(1,003,865)
Balances at Dec. 31, 2019	$ 19,381	2,756,798	(3,672,077)	366	(895,532)
Balances (in Shares) at Dec. 31, 2019	19,380,460
Fair value of stock options vested		30,207			30,207
Issuance of common stock for services	$ 147	207,585			207,732
Issuance of common stock for services (in Shares)	147,798
Common stock issued in debt extinguishment	$ 100	149,900			150,000
Common stock issued in debt extinguishment (in Shares)	100,000
Foreign currency translation adjustment				(4,446)	(4,446)
Net loss			(4,284,785)		(4,284,785)
Balances at Dec. 31, 2020	$ 19,628	$ 3,144,490	$ (7,956,862)	$ (4,080)	$ (4,796,824)
Balances (in Shares) at Dec. 31, 2020	19,628,258

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,284,785)	$ (1,003,865)
Change in net loss to net cash used in operating activities:
Depreciation and amortization expense	1,372	1,330
Amortization of debt discount and non-cash interest expense	3,312,733
Change in fair value of derivative liabilities	(1,360,754)
Loss on debt extinguishment	294,301
Fair value of stock options vested	30,207	12,797
Common stock issued for services	207,732	17,720
Changes in operating assets and liabilities:
Accounts receivable	4,095	(5,555)
Inventory	(1,461)	(7,085)
Prepaid expenses and other current assets	(72,170)	(700)
Accounts payable and accrued expenses	696,330	159,441
Accounts payable - related party	(2,663)	(22,637)
Other liabilities	(1,782)	(6,172)
Operating lease liabilities, net	3,436
NET CASH USED IN OPERATING ACTIVITIES	(1,173,409)	(854,726)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(1,005)
NET CASH USED IN INVESTING ACTIVITIES		(1,005)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible notes payable	897,700	630,000
Proceeds from note payable	285,000	50,000
Proceeds from loans payable	6,667	273,084
Capital contribution - related party		154
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,189,367	953,238
Effect of exchange rate changes on cash	(4,538)	366
NET CHANGE IN CASH	11,420	97,873
CASH AT BEGINNING OF THE YEAR	261,436	163,563
CASH AT END OF THE YEAR	272,856	261,436
Supplemental Disclosure of Cash Flow Information
Cash paid for interest	9,867
Cash paid for taxes
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Discounts related to warrants issued in connection with convertible debentures		130,768
Debt discount and derivative liability associated with convertible and non-convertible notes payable	1,330,752
Write off of related party accounts payable		$ 500

Organization and Nature of Oper

Organization and Nature of Operations	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND NATURE OF OPERATIONS	Brain Scientific Inc. (the “Company”), was incorporated under the laws of the state of Nevada on November 18, 2013 under the name All Soft Gels Inc. The Company on September 21, 2018 acquired MemoryMD, Inc. (“MemoryMD”), a privately held Delaware corporation formed in February 2015. Upon completion of the acquisition, MemoryMD is treated as the surviving entity and accounting acquirer although the Company was the legal acquirer. Accordingly, the Company’s historical financial statements are those of MemoryMD, the surviving entity and accounting acquirer. MemoryMD is a cloud computing, data analytics and medical device technology company in the NeuroTech and brain monitoring industries seeking to commercialize its EEG devices and caps. The Company is headquartered in New York. Reverse Merger and Corporate Restructure On September 21, 2018, the Company entered into a merger agreement (the “Merger Agreement”) with MemoryMD and AFGG Acquisition Corp. to acquire MemoryMD (the “Acquisition”). The transactions contemplated by the Merger Agreement were consummated on September 21, 2018 and, pursuant to the terms of the Merger Agreement, all outstanding shares of MemoryMD were exchanged for shares of the Company’s common stock. Accordingly, the Company acquired 100% of MemoryMD in exchange for the issuance of shares of the Company’s common stock and MemoryMD became the Company’s wholly owned subsidiary. The Company issued an additional 4,083,252 shares of its common stock upon the automatic conversion at the closing of an aggregate of $1,507,000 principal amount plus accrued interest of outstanding convertible promissory notes issued by MemoryMD, and it further issued an additional 1,604,378 shares of its common stock upon the automatic conversion immediately subsequent to the closing of an aggregate of $640,000 principal amount plus accrued interest of outstanding convertible promissory notes issued by MemoryMD. Furthermore, as of the closing, Mr. Amer Samad, the sole director and executive officer until the consummation of the Acquisition, committed to tender for cancellation 6,495,000 shares of the Company’s common stock as part of the conditions to closing, of which 6,375,000 have been cancelled at December 31, 2018 and 120,000 are expected to be cancelled as soon as practicable. Total shares issued as a result of the Acquisition was 13,421,752. The Acquisition has been accounted for as a reverse recapitalization of Brain Scientific by MemoryMD, but in substance as a capital transaction, rather than a business combination since Brain Scientific had nominal or no operations and assets prior to and as of the closing of the Acquisition. The transaction is deemed a reverse recapitalization and the accounting is similar to that resulting from a reverse acquisition, except that no goodwill or other intangible assets should be recorded. For accounting purposes, MemoryMD is treated as the surviving entity and accounting acquirer although Brain Scientific was the legal acquirer. Accordingly, the Company’s historical financial statements are those of MemoryMD. All references to common stock, share and per share amounts have been retroactively restated to reflect the reverse recapitalization as if the transaction had taken place as of the beginning of the earliest period presented. Assignment and Assumption Agreement As of immediately prior to the closing of the Acquisition, the Company entered into an Assignment and Assumption Agreement with Chromium 24 LLC, pursuant to which Chromium 24 LLC assumed all of the Company’s remaining assets and liabilities through the closing of the Acquisition. Accordingly, as of the closing of the Acquisition, Brain Scientific had no assets or liabilities other than the shares of MemoryMD acquired in the Acquisition. Name Change and Increase in Authorized Shares On September 18, 2018, the Company filed an amendment to its certificate of incorporation with the Nevada Secretary of State to change its name to Brain Scientific Inc. On September 18, 2018, FINRA approved of the name change as well as a ticker symbol change, which was effective as of September 19, 2018. In addition, the Company increased its authorized shares of common stock from 50,000,000 to 200,000,000 and created and authorized 10,000,000 shares of undesignated preferred stock.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with GAAP. Principles of Consolidation The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (“ASC 810”). The consolidated financial statements include the accounts of the Company and its subsidiaries, MemoryMD and MemoryMD - Russia. The operations of the newly formed 100% wholly owned subsidiaries, MemoryMD – Russia and MemoryMD Europe, are included beginning April 1, 2019 and July 1, 2019, respectively. All significant consolidated transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the useful life of property and equipment and assumptions used in the valuation of options and warrants. The Effects of COVID-19 The World Health Organization (WHO) declared the coronavirus outbreak a pandemic on January 30, 2020. Since the outbreak in China in December 2019, COVID-19 has expanded its impact to Europe, where all of our operations reside, as well as our employees, suppliers and customers. While the disruption is currently expected to be temporary, there is considerable uncertainty around the duration of the closings and shelter-in-place orders and the ultimate impact of governmental initiatives. However, the financial impact and duration cannot be reasonably estimated at this time. Cash and Cash Equivalents The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At December 31, 2020 and December 31, 2019, the Company had no cash equivalents. The Company’s cash is held with financial institutions, and the account balances may, at times, exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit. Accounts are insured by the FDIC up to $250,000 per financial institution. The Company has not experienced any losses in such accounts with these financial institutions. As of December 31, 2020 and December 31, 2019, the Company had $22,856 and $11,436, respectively, in excess over the FDIC insurance limit. Accounts Receivable Accounts receivable are carried at net realizable value and are reviewed for collectibility on an ongoing basis. For the years ended December 31, 2020 and 2019, the Company did not recognize any allowances for doubtful accounts. Inventory Inventory consists of finished goods that are valued at lower of cost or market using the weighted average method. As of December 31, 2020, and December 31, 2019, the Company had inventory totaling $1,461 and $0, respectively. Property and Equipment Property and equipment are recorded at cost, less depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Expenditures for repair and maintenance are charged to operations as incurred. Property and equipment consisted of computer equipment, with an estimated useful life of three years. Convertible Notes Payable The Company has issued convertible notes, which contain variable conversion features, whereby the outstanding principal and accrued interest automatically convert into common shares at a fixed price which may be a discount to the common stock at the time of conversion. Some of the conversion features of these notes are contingent upon future events, whereby, the holder agreed not to convert until the contingent future event has occurred. Derivative Instruments The Company evaluates its convertible notes and warrants to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815. The result of this accounting treatment is that the fair value of the embedded derivative is recorded as a liability and marked-to-market each balance sheet date. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statements of operations as other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. The Company utilizes the Monte Carlo Method that values the liability of the debt conversion feature, derivative financial instruments and derivative warrants in cases where there may be multiple embedded features or the features of the bifurcated derivatives may be so complex that a Black-Scholes valuation does not consider all of the terms of the instrument. Therefore, the fair value may not be appropriately captured by simple models. The Monte Carlo technique applied generates many possible (but random) price paths for the underlying (or underlyings) via simulation, and then calculates the associated payment value of the derivative features. The price of the underlying common stock is modeled such that it follows a geometric Brownian motion with constant drift, and constant volatility. The stock price is determined by a random sampling from a normal distribution. Since the underlying random process is the same, for enough price paths, the value of derivative is derived from path dependent scenarios and outcomes. The Company also applied a Black Scholes (“BSM”) analysis for the tainted notes and tainted warrants with simple fixed conversion and exercise prices. The BSM derivative valuation assumes these tainted securities are held till maturity. From time to time, certain of the Company’s embedded conversion features on debt and outstanding warrants have been treated as derivative liabilities for accounting purposes under ASC 815 due to insufficient authorized shares to fully settle conversion features of the instruments if exercised. In this case, the Company utilized the latest inception date sequencing method to reclassify outstanding instruments as derivative instruments. These contracts were recognized at fair value with changes in fair value recognized in earnings until such time as the conditions giving rise to such derivative liability classification were settled. Leases In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires lessees to recognize most leases on their balance sheets as a right-of-use asset with a corresponding lease liability. Lessor accounting under the standard is substantially unchanged. Additional qualitative and quantitative disclosures are also required. The Company adopted the standard effective January 1, 2019 using the cumulative-effect adjustment transition method, which applies the provisions of the standard at the effective date without adjusting the comparative periods presented. The Company adopted the following practical expedients and elected the following accounting policies related to this standard update: ● Short-term lease accounting policy election allowing lessees to not recognize right-of-use assets and liabilities for leases with a term of 12 months or less. ● The option to not separate lease and non-lease components for certain equipment lease asset categories such as freight car, vehicles and work equipment. As a result of the above, the adoption of ASC 842 did not have a material effect on the consolidated financial statements. Revenue Recognition On January 1, 2018, the Company adopted ASC Topic 606 Revenue from Contracts with Customers. This guidance requires an entity to recognize revenue by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Once the steps are met, revenue is recognized, generally upon receiving a letter of acceptance from the customer. There has been no material effect on the Company’s financial statements as a result of adopting Topic 606. The Company recognizes revenue from the sale of NeuroCaps, as well as revenue from the sale of goods purchased through manufacturers of medical devices. Primarily all revenue for the years ended December 31, 2020 and 2019 is from the sale of medical devices purchased from Neurotech, a related party. Research and Development The Company expenses all research and development costs as they are incurred. Research and development includes expenditures in connection with in-house research and development salaries and staff costs, application and filing for regulatory approval of proposed products, regulatory and scientific consulting fees, as well as contract research, data collection, and monitoring, related to the research and development of the cloud infrastructure, data imaging, and proprietary products and technology. Research and development costs recognized in the statement of operations for the years ended December 31, 2020 and 2019 were $275,926 and $103,616, respectively. Sales and Marketing Advertising and marketing costs are expensed as incurred. Advertising and marketing costs recognized in the statement of operations for the years ended December 31, 2020 and 2019 were $244,774 and $95,165, respectively. Stock-based Compensation The Company measures and recognizes compensation expense for all stock-based payments at fair value over the requisite service period. The Company uses the Black-Scholes option pricing model to determine the weighted average fair value of options and warrants. Equity-based compensation expense is recorded in administrative expenses based on the classification of the employee or vendor. The determination of fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as by assumptions regarding a number of subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. In the years ended December 31, 2020 and 2019, 7,415,040 and 1,502,250, respectively, of anti-dilutive securities were excluded from the computation. Fair Value of Financial Instruments The Company’s financial instruments are measured and recorded at fair value based on inputs and assumptions that market participants would use in pricing an asset or a liability. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, management considers the principal or most advantageous market in which the Company would transact, and also considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance. Fair value is determined for assets and liabilities using a three-tiered value hierarchy into which these assets and liabilities are grouped based upon significant inputs as follows: ● Level 1 - Quoted prices in active markets for identical assets or liabilities. ● Level 2 - Observable inputs, other than Level 1 prices, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. ● Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. When a determination is made to classify a financial instrument within Level 3, the determination is based upon the lack of significance of the observable parameters to the overall fair value measurement. However, the fair value determination for Level 3 financial instruments may consider some observable market inputs. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy. The carrying values of cash, prepaid expenses and other current assets, convertible notes, accounts payable, loans payable and due to others approximate fair value due to the short-term nature of these items. The Company did not have any Level 1 or Level 2 assets or liabilities as of December 31, 2020 and the Company did not have any other Level 1, Level 2 or Level 3 assets or liabilities as of December 31, 2019. Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the consolidated balance sheet as of December 31, 2020. Liabilities Amounts at Level 1 Level 2 Level 3 Derivative liability – conversion feature $ 345,708 $ - $ - $ 345,708 Derivative liability - warrants 2,217,234 - - 2,217,234 Total $ 2,562,942 $ - $ - $ 2,562,942 Income Taxes The Company accounts for income taxes using the asset-and-liability method in accordance with ASC Topic 740, “Income Taxes”. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is recognized in the period that includes the enactment date. A valuation allowance is recorded if it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized in future periods. The Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely-than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties related to tax positions in income tax expense. As of December 31, 2020, and December 31, 2019, the Company had no unrecognized uncertain income tax positions. Recent Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on the Company’s financial position or results of operations upon adoption. In June 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2016-13, “Measurement of Credit Losses on Financial Instruments,” which requires measurement and recognition of expected credit losses at the point a loss is probable to occur, rather than expected to occur, which will generally result in earlier recognition of allowances for credit losses. The new guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted ASU 2016-13 in the first quarter of 2020 and the adoption did not have a material impact on its condensed consolidated financial statements.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2020
Going Concern [Abstract]
GOING CONCERN	NOTE 3 – GOING CONCERN The accompanying financial statements have been prepared in conformity with U.S. GAAP, which contemplate continuation of the Company as a going concern for a period of one year from the issuance of these financial statements. For the year ended December 31, 2020, the Company had $544,275 in revenues, a net loss of $4,284,785 and had net cash used in operations of $1,173,409. Additionally, as of December 31, 2020, the Company had working capital deficit, stockholders’ deficit and accumulated deficit of $4,765,850, $4,796,824 and $7,956,862, respectively. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the date of the issuance of these financial statements. The financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities, acceptance of the Company’s patent applications and ultimately achieving a level of sales adequate to support the Company’s cost structure. However, there can be no assurances that the Company will be able to secure additional equity investments or achieve an adequate sales level.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 4 – PROPERTY AND EQUIPMENT Property and equipment, net consists of the following: December 31, 2020 December 31, 2019 Computer equipment $ 4,105 $ 4,105 Less: Accumulated depreciation (3,807 ) (2,431 ) Total $ 302 $ 1,674 Depreciation expense was $1,372 and $1,330 for the years ended December 31, 2020 and 2019, respectively.

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
CONVERTIBLE NOTES PAYABLE	NOTE 5 – CONVERTIBLE NOTES PAYABLE January 2019 Debt Offering In January 2019, the Company commenced an offering of up to $500,000 pursuant to which the Company will issue convertible notes to investors. On January 18, 2019, February 5, 2019 and July 23, 2019, the Company issued three such convertible notes payable to three investors for $100,000, $130,000 and $150,000, respectively. The notes bear interest at a fixed rate of 10% per annum, computed based on a 360-day year and mature on the earlier of one year from the date of issuance or the consummation of an equity or equity-linked round of financing of the Company in excess of $1,000,000 (“Qualified Financing”) or other event pursuant to which conversion shares are to be issued pursuant to the terms of the note. On February 28, 2020, the Company and the holder of the January 18, 2019 convertible note agreed to extend the maturity date of the January 18, 2019 convertible note to January 18, 2021. On February 24, 2021, the January 18, 2019 convertible note was further extended to January 18, 2022. On February 28, 2020, the Company and the holder of the February 5, 2019 convertible note agreed to extend the maturity date of the February 5, 2019 convertible note to February 5, 2021. On February 24, 2021, the February 5, 2019 convertible note was further extended to February 5, 2022. On July 22, 2020 the Company and the holder of the July 23, 2019 convertible note agreed to extend the maturity date of July 23, 2020 to February 21, 2021. On February 24, 2021, the July 23, 2019 convertible note was further extended to February 21, 2022. The notes are convertible into common stock of the Company following events on the following terms: with no action on the part of the note holder upon the consummation of a Qualified Financing, the debt will be converted to new round stock based on the product of the outstanding principal and accrued interest multiplied by 1.35, then divided by the accrual per share price of the new round common stock. If a change of control occurs or if the Company completes a firmly underwritten public offering of its common stock prior to the Qualified Financing the notes would, at the election of the holders of a majority of the outstanding principal of the notes, be either payable on demand as of the closing of such change of control or Initial Public Offering (“IPO”) or convertible into shares of common stock immediately prior to such change of control transaction or IPO transaction at a price per share equal to the lesser of the per share value of the common stock as determined by the Company’s Board of Directors or the per share consideration to be received by the holders of the common stock in such change of control or IPO transaction. Based on the terms of the conversion, the holders may receive a discount, and the notes are considered to have a contingent beneficial conversion feature. If conversion of the debt occurs, the Company will recognize an expense related to the intrinsic value. The Company recorded $66,035 of accrued interest and has a total outstanding principal balance of $380,000 as of December 31, 2020. In the event that the Company consummates a financing prior to the maturity date, other than a Qualified Financing, and the economic terms thereof are more favorable to the investors in such financing than the terms of the note, the note shall automatically be amended to reflect such more favorable economic terms. December 31, 2019 Securities Purchase Agreement On December 31, 2019, the Company entered into a Securities Purchase Agreement and issued and sold to a third party a Convertible Note in the original principal amount of $275,000 (the “Note”), and a warrant to purchase 100,000 shares of the Company’s common stock (the “Warrant”). The aggregate purchase price received by the Company was $250,000 after an original issue discount of $25,000. A one-time interest charge of 8% was applied on December 31, 2019 and will be payable, along with the Principal, on July 31, 2020 (the “Maturity Date”), as may be extended at the option of the Investor. The unpaid outstanding principal amount and accrued and unpaid interest under the Note shall be convertible into shares of the Company’s common stock at any time at the option of the investor. The conversion price shall be equal to 80% multiplied by the price per share paid by the investors in the next capital raising transaction consummated by the Company in the amount of $1,000,000 or more (the “Qualified Financing”), subject to adjustments as provided in the Note. In the event the investor elects to convert the Note prior to a Qualified Financing, the conversion price shall be the effective exercise price per share from time to time pursuant to the Warrant. At any time prior to the maturity date of the Note, upon 10 business days’ notice to the investor, the Company shall have the right to pre-pay the entire remaining principal amount of the Note subject to the pre-payment terms contained in the Note. The Note contains a price-based anti-dilution provision, pursuant to which the conversion price of the Note shall be reduced upon the occurrence of certain dilutive issuances of Company securities as set forth in the Note. The conversion of the Note is also subject to a beneficial ownership limitation of 4.99% of the number of shares of common stock outstanding immediately after giving effect to such conversion. In the event the Company, prior to the maturity date of the Note, issues any Security (as defined in the Note) with any term more favorable to the holder of such Security or with a term in favor of the holder of such Security that was not similarly provided to the Investor, then at the Investor’s option such term shall become a part of the Note. The Company also agreed to provide piggy-back registration rights to the investor pursuant to which the Company shall include all shares issuable upon conversion of the Note on the next registration statement the Company files with the Securities and Exchange Commission. The Note contains events of default which, among other things, entitle the Investor to accelerate the due date of the unpaid principal amount of, and all accrued and unpaid interest on, the Note. Upon the occurrence of any event of default, the outstanding balance shall immediately and automatically increase to 130% of the outstanding balance immediately prior to the event of default, and the conversion price of the Note shall be redefined to equal 65% of the lowest trade accruing during the 10 consecutive Trading Days (as defined in the Note) immediately preceding the applicable Conversion Date (as defined in the Note). Nickolay Kukekov, a director of the Company, and a third party, each has personally guaranteed the repayment of the Note. The Warrant has an exercise price of $1.25 per share (the “Exercise Price”), subject to adjustments as provided in the Warrant, and has a term of five years. The Warrant contains a price-based anti-dilution provision, pursuant to which the exercise price of the Warrant shall be reduced upon the occurrence of certain dilutive issuances of securities as set forth in the Warrant, with a corresponding increase in the number of shares underlying the Warrant if the dilutive event occurs during the first three years of the Warrant, and a cashless exercise provision. The exercise of the Warrant is subject to a beneficial ownership limitation of 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. The Company calculated the Warrants at fair value of $130,768 using the Monte Carlo model, which was recognized as a discount to the Note and is being amortized as interest expense over the remaining term of the notes. The Note is considered a derivative liability due to the variable market-based conversion price upon default. The Warrant is accounted for as a discount to the Note, and therefore fair valued and recorded as a derivative liability as well. On March 18, 2020, the Warrant was revalued and recorded as a derivative liability in the amount of $255,899. On December 31, 2020, the Warrant derivative was valued at $109,026. For the year ended December 31, 2020, the Company recorded a gain on the change in fair market value of derivative liabilities in the amount of $146,873 in relation to the Warrant derivative. On August 5, 2020, the Company entered into an Allonge to the Convertible Note, dated as of August 8, 2020, which amended the Note. The allonge amended the Note by, among other things, extending the maturity date of the loan until October 31, 2020. As consideration for the allonge, the original principal amount was increased by ten percent, and the Company agreed to issue 50,000 shares of its common stock to the investor that were valued at fair market value of $75,000. The Company evaluated the allonge for debt modification in accordance with ASC 470-50 and concluded that the debt qualified for debt extinguishment as the 10% cash flow test was met. As a result, the $297,000 of principal and accrued interest was written off, new debt was recorded at fair value as of August 5, 2020 in the amount of $324,500 and the Company recorded a net loss on extinguishment of debt in the amount of $176,467. On October 29, 2020, the Company entered into a second Allonge to the Convertible Note which amended the Note. The allonge amended the Note by, among other things, extending the maturity date of the loan until January 31, 2021. As consideration for the allonge, the original principal amount was increased by ten percent, and the Company agreed to issue 50,000 shares of its common stock to the investor that were valued at fair market value of $75,000. The Company evaluated the allonge for debt modification in accordance with ASC 470-50 and concluded that the debt qualified for debt extinguishment as the 10% cash flow test was met. As a result, the $324,500 of principal and accrued interest was written off, new debt was recorded at fair value as of October 29, 2020 in the amount of $359,370 and the Company recorded a net loss on extinguishment of debt in the amount of $115,524. On December 28, 2020, the Company issued a non-convertible promissory note with interest terms that were more favorable than the terms of the Convertible Note. As a result of that issuance, certain abovementioned terms of the Convertible Note were triggered which reset the interest rate of the Convertible Note to 12%. The effect of the interest rate reset resulted in increases of $2,310 to the balance of the Convertible Note, $11,000 of accrued interest, $11,000 of interest expense and $2,310 of loss on extinguishment of debt. For the year ended December 31, 2020, the Company recorded a net loss on extinguishment of debt in the amount of $294,301. The Company has a total outstanding principal balance under the Note of $339,680 and $33,000 of accrued interest as of December 31, 2020. In the year ended December 31, 2019, the Company recorded a total debt discount of $155,768 related to the above convertible notes. During the year ended December 31, 2020 the Company recorded an additional debt discount of $176,274 related to the above convertible notes. Amortization of the debt discount is recorded as interest expense and a total of $332,042 was amortized during the year ended December 31, 2020. Subsequent to the balance sheet date, due to the partial conversion of an outstanding convertible loan, certain anti-dilution provisions were triggered, resulting in the reset of the warrant amounts, warrant exercise price and the conversion price. Please see Note 15. Convertible Grid Notes On April 21, 2020, the Company issued a Convertible Grid Promissory Note (the “Caleca Note”) to Thomas J. Caleca (“Caleca”), an existing stockholder of the Company, pursuant to which Caleca agreed to advance to the Company the aggregate principal amount of $125,000 (the “Caleca Aggregate Advance”). The Company also issued to Caleca a common stock purchase warrant (the “Caleca Warrant”), granting Caleca the right to purchase up to 750,000 shares of the Company’s common stock at a per share exercise price of $0.80 (subject to adjustment as set forth in the Caleca Warrant). Also on April 21, 2020, the Company issued a Convertible Grid Promissory Note (the “Brown Note”, and together with the Caleca Note, the “Grid Notes”) to Andrew Brown (“Brown”, and together with Caleca, the “Grid Investors”), an existing stockholder of the Company, pursuant to which Brown agreed to advance to the Company the aggregate principal amount of $125,000 (the “Brown Aggregate Advance”, and together with the Caleca Aggregate Advance, the “Aggregate Advance”). The Company also issued to Brown a common stock purchase warrant (the “Brown Warrant”, and together with the Caleca Warrant, the “Grid Warrants”), granting Brown the right to purchase up to 750,000 shares of the Company’s common stock at a per share exercise price of $0.80 (subject to adjustment as set forth in the Brown Warrant). The Grid Warrants are exercisable at any time commencing on the eighteen-month anniversary of the issuance of the Grid Warrants (as may be accelerated pursuant to the terms of the Grid Warrants) and expiring on the five-year anniversary of the issuance of the Grid Warrants. On April 22, 2020, the Grid Investors each made their first cash advance of $25,000 pursuant to the terms of the Grid Notes, for an aggregate cash advance to the Company of $50,000 (the “First Advance”). The Grid Investors made additional cash advances to the Company pursuant to the terms of their Grid Notes. As of December 31, 2020, a total of $250,000 in principal was advanced to the Company. During the year ended December 31, 2020, the Company recorded debt discount of $233,893 related to the Grid Notes. Amortization of the debt discount is recorded as interest expense and a total of $159,917 was amortized during the year ended December 31, 2020. The Grid Notes bear interest on the unpaid balances at a fixed simple rate of twelve percent (12%) per annum (subject to a rate increase if the Company commits an Event of Default (as defined in the Grid Notes)), computed based on a 360-day year of twelve 30-day months, commencing on the date of the respective advance and payable quarterly. The principal amount of the Aggregate Advance, or so much thereof as has been advanced to the Company by the Grid Investors from time to time pursuant to the Grid Notes, will be payable on April 21, 2021, unless sooner converted into shares of the Company’s common stock pursuant to the terms of the Grid Notes. The Company recorded $17,532 of accrued interest and has a total outstanding principal balance of $250,000 as of December 31, 2020. The unpaid outstanding principal amount and accrued and unpaid interest under the Grid Notes shall be convertible at any time prior to the maturity date of the Grid Notes at the election of the Grid Investors into such number of shares of the Company’s common stock obtained by dividing the amount so converted by $1.00 (the “Conversion Price”). At the maturity date of the Grid Notes, all of the remaining unpaid outstanding principal amount and accrued and unpaid interest (the “Outstanding Balance”) under the Grid Notes shall automatically convert into such number of shares of the Company’s common stock obtained by dividing the Outstanding Balance by the Conversion Price. The Grid Notes may not be prepaid by the Company in whole or in part without the prior written consent of the respective Grid Investor. The Grid Notes contain customary events of default, which, if uncured, entitle the Grid Investors to accelerate the due date of the unpaid principal amount of, and all accrued and unpaid interest on, their Grid Notes. September 1, 2020 Securities Purchase Agreement On September 1, 2020 (the “September 1 Issuance Date”), the Company entered into a Securities Purchase Agreement and issued and sold to an investor an 8% Convertible Redeemable Note in the original principal amount of $157,500 (the “September 1 Note”). The net amount received by the Company for the sale of the September 1 Note was $142,500 after an original issue discount of $15,000 and after payment of the investor’s legal fees. The September 1 Note bears interest commencing on the September 1 Issuance Date at a fixed rate of 8% per annum on any unpaid principal balance, and will be payable, along with the principal amount, on September 1, 2021, unless such interest is earlier converted into shares of the Company’s common stock pursuant to the conversion terms contained in the September 1 Note. During the year ended December 31, 2020, the Company recorded debt discount of $157,500 related to the September 1 Note. Amortization of the debt discount is recorded as interest expense and a total of $54,370 was amortized during the year ended December 31, 2020. On December 28, 2020, the Company issued a non-convertible promissory note with interest terms that were more favorable than the terms of the Convertible Note. As a result of that issuance, certain terms of the Convertible Note mentioned below were triggered which reset the interest rate of the Convertible Note to 12%. The Company recorded $6,471 of accrued interest and has a total outstanding principal balance of $157,500 as of December 31, 2020. The unpaid outstanding principal amount and accrued and unpaid interest under the September 1 Note shall be convertible into shares of common stock at any time on or after the September 1 Issuance Date at the option of the investor. The conversion price shall be equal to 60% of the lowest closing bid price for the common stock, subject to certain exceptions and adjustments contained in the September 1 Note, for the fifteen prior trading day period. From the September 1 Issuance Date until 180 days after the September 1 Issuance Date, upon 3 days’ notice to the investor, the Company shall have the right to pre-pay the entire remaining principal amount of the September 1 Note, subject to the pre-payment terms contained in the September 1 Note. The conversion of the September 1 Note is subject to a beneficial ownership limitation of 4.99% (or 9.9% upon notice of the investor) of the number of shares of common stock outstanding immediately after giving effect to such conversion. The September 1 Note is further subject to a “most-favored nation” clause in the event the Company offers a more favorable conversion discount, interest rate, look back period or other more favorable term to another party for any financings while the September 1 Note is in effect, subject to certain exceptions contained in the September 1 Note. The September 1 Note contains customary events of default which entitle the investor, among other things, to accelerate the due date of the unpaid principal amount of, and all accrued and unpaid interest on, the September 1 Note. Upon an event of default, interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. The September 1 Note further contains monetary penalties in the event of certain events of default. At the investor’s election, if the Company fails for any reason to deliver to the investor underlying shares upon conversion by the 3rd business day thereafter and if the investor incurs a Failure to Deliver Loss (as defined in the September 1 Note), then the Company must make the investor whole in relation to such loss. Upon certain sale events as specified in the September 1 Note, the Company shall, upon request of the investor, redeem the September 1 Note in cash for 150% of the principal amount, plus accrued but unpaid interest through the date of redemption, or at the election of the investor, such Holder may convert the unpaid principal amount of the September 1 Note (together with the amount of accrued but unpaid interest) into shares of Company common stock immediately prior to such sale event at the conversion price specified in the September 1 Note. September 22, 2020 Securities Purchase Agreement On September 22, 2020, the Company entered into a Securities Purchase Agreement (the “September Purchase Agreement”) dated as of September 22, 2020 (the “September 22 Issuance Date”) and issued and sold to an investor a Promissory Note (the “September 22 Note”) in the aggregate original principal amount of $600,000, of which $100,000 aggregate principal amount was borrowed as of the Issuance Date with the balance of the principal borrowed on October 19, 2020. Also pursuant to the September Purchase Agreement, in connection with the issuance of the September Note, the Company issued two common stock purchase warrants (separately, “Warrant A” and “Warrant B”, and together, the “September Warrants”) to the investor, allowing the investor to purchase an aggregate of 1,411,764 shares of the Company’s common stock, with Warrant A being a commitment fee of 705,882 shares of common stock, and Warrant B being fully earned upon issuance as an additional commitment fee of 705,882 shares of common stock, provide that Warrant B is returnable to the Company upon the repayment of the September 22 Note, as an additional incentive for the repayment of the September 22 Note. The net amount received by the Company during the year ended December 31, 2020 was approximately $505,000 after payment of certain fees to the investor or on behalf of the investor. In the event the Company breaches any of the covenants set forth in Section 4 of the Purchase Agreement, and in addition to any other remedies available to the Buyer pursuant to the Purchase Agreement, it will be considered an Event of Default under the September 22 Note and the Company shall pay to the Buyer certain liquidated damages as set forth in the September 22 Note in cash or in shares of common stock at the option of the Buyer. If the Buyer elects to have the Company pay such liquidated damages in shares of common stock, such shares shall be issued at the conversion price at the time of payment. The September 22 Note bears interest commencing on the September 22 Issuance Date at a fixed rate of 12% per annum on any unpaid principal balance, and will be payable, along with the principal amount, on September 22, 2021, unless such interest is earlier converted into shares of the common stock pursuant to the conversion terms contained in the September 22 Note. A lump-sum interest payment for one year is due on the September 22 Issuance Date and added to the principal balance and payable on the maturity date of the September 22 Note or upon acceleration or by prepayment or otherwise, notwithstanding the number of days which the principal is outstanding. Principal payments shall be made in 6 installments each in the amount of $100,000 commencing 180 days following the applicable Issue Date (as defined in the Note) and continuing thereafter each 30 days for 5 months. During the year ended December 31, 2020, the Company recorded debt discount of $600,000 related to the September 22 Note. Amortization of the debt discount is recorded as interest expense and a total of $105,815 was amortized during the year ended December 31, 2020. The Company has a total outstanding principal balance of $600,000 as of December 31, 2020. The unpaid outstanding principal amount and accrued and unpaid interest under the September 22 Note shall be convertible into shares of common stock at any time on or after the September 22 Issuance Date at the option of the investor. The conversion price shall be equal to the lesser of (subject to equitable adjustments): (i) the lowest Market Price (as defined in the September 22 Note) during the previous five Trading Day (as defined in the September 22 Note) period ending on the latest complete Trading Day prior to the September 22 Issuance Date, and (ii) the Variable Conversion Price (as defined in the September 22 Note). The conversion price shall be adjusted downwards upon certain events as set forth in the September 22 Note. The September 22 Note is subject to adjustment in the event of certain events, including mergers or consolidations of the Company, distributions of assets to holders of common stock, stock repurchases, and dilutive issuances (other than “Exempt Issuances” as defined in the September 22 Note). Provided that an event of default under the September 22 Note has not occurred, the Company may prepay in whole or in part the amounts outstanding under the September 22 Note by making a payment to the investor of an amount in cash equal to the sum of: (w) the then outstanding principal amount of the September 22 Note plus (x) accrued and unpaid interest on the unpaid principal amount of the September 22 Note plus (y) default interest, if any. The conversion of the September 22 Note and the exercise of the Warrants are subject to a beneficial ownership limitation of 4.99% of the number of shares of common stock outstanding immediately after giving effect to such conversion or exercise, as the case may be. The September 22 Note contains customary events of default which entitle the investor, among other things, to accelerate the due date of the unpaid principal amount of, and all accrued and unpaid interest on, the September 22 Note. Upon an event of default, interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. The September 22 Note further contains monetary penalties in the event of certain events of default or breaches. The September 22 Note is further subject to a “most-favored nation” clause in the event the Company issues any security with any term more favorable to the holder of such security. The September Warrants each have an exercise price of $1.28, subject to customary adjustments, and may be exercised at any time until the three-year anniversary of the September Warrants; provided, however, in the event the Company repays the September 22 Note in its entirety on or prior to the maturity date of the September 22 Note, Warrant B shall automatically expire and may only be exercised in the event it does not so automatically expire. The September Warrants include a cashless exercise provision as set forth therein. On December 28, 2020, the Company issued a non-convertible promissory note with a warrant exercise price that was more favorable than the terms of the September 22 Note. The amount of shares under the September Warrants was reset to 1,505,882 with an exercise price of $1.20. Derivative Accounting for the Convertible Notes Payable The Company evaluated the terms and conditions of the Note, the Grid Notes, the September 1 Note and the September 22 Note under the guidance of ASC 815. The conversion terms of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock. The number of shares of common stock to be issued is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the promissory note is indeterminate. Due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit, the equity environment is tainted, and all additional convertible debentures and warrants are included in the value of the derivative liabilities. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the variable conversion options and warrants and shares to be issued were recorded as derivative liabilities on the issuance date and revalued at each reporting period. (see Note 7) Certain of the Company’s embedded conversion features on debt and outstanding warrants are treated as derivative liabilities for accounting purposes under ASC 815 due to insufficient authorized shares to settle these outstanding contracts, or due to other rights connected with these contracts, such as registration rights. In the case of insufficient authorized share capital available to fully settle outstanding contracts, the Company utilizes the issuance date sequencing method to reclassify outstanding contracts as derivative instruments. These instruments do not trade in an active securities market.

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2020
Notes Payable [Abstract]
NOTES PAYABLE	NOTE 6 – NOTES PAYABLE On October 23, 2019, an investor of the Company subscribed for a promissory note (the “October Note”) and loaned to the Company $50,000. The October Note bears interest at a fixed rate of 14% per annum, computed based on a 360-day year of twelve 30-day months, which interest will be payable quarterly until the maturity date. The principal amount and any accrued and unpaid interest due under the October Note was originally to mature on October 21, 2020, subject to a thirty-day grace period. On November 13, 2020, the Company entered into an allonge with the investor that extended the maturity date of the note to April 21, 2021. During the year ended December 31, 2020 the Company recorded $6,996 of interest expense and has a total outstanding principal balance of $50,000 and accrued interest of $1,356 as of December 31, 2020. The October Note contains customary events of default, which, if uncured, entitle the lender to accelerate the due date of the unpaid principal amount of, and all accrued and unpaid interest on, the October Note. February 21, 2020 Note On February 21, 2020, a third party loaned the Company $20,000, evidenced by a non-convertible promissory note (the “February Note”).The February Note bears interest at a fixed rate of 12% per annum, computed based on a 360-day year of twelve 30-day months, which interest will be payable quarterly until the maturity date. The principal amount and any accrued and unpaid interest due under the February Note were originally payable on July 1, 2020. On July 28, 2020 the Company entered into an allonge, effective July 1, 2020, to extend the original maturity date to February 21, 2021. The Company recorded $2,060 of accrued interest and has a total outstanding principal balance of $20,000 as of December 31, 2020. The February Note contains customary events of default, which, if uncured, entitle the lender to accelerate the due date of the unpaid principal amount of, and all accrued and unpaid interest on, the February Note. December 28, 2020 Note On December 28, 2020, the Company entered into a Securities Purchase Agreement (the “December Purchase Agreement”) dated as of December 28, 2020 (the “December 28 Issuance Date”) and issued and sold to an investor a Promissory Note (the “December 28 Note”) in the aggregate principal amount of $300,000. Pursuant to the December Purchase Agreement, in connection with the issuance of the December 28 Note, the Company issued two common stock purchase warrants (separately, “Warrant A” and “Warrant B”, and together, the “December Warrants”) to the investor, allowing the investor to purchase an aggregate of 500,000 shares of the Company’s common stock, with Warrant A being a commitment fee of 250,000 shares of common stock, and Warrant B being fully earned upon issuance as an additional commitment fee of 250,000 shares of common stock, provide that Warrant B is returnable to the Company upon the repayment of the December 28 Note, as an additional incentive for the repayment of the December 28 Note. The net amount received by the Company during the year ended December 31, 2020 was approximately $265,000 after payment of certain fees to the investor or on behalf of the investor. The December 28 Note bears interest commencing on the December 28 Issuance Date at a fixed rate of 12% per annum on any unpaid principal balance, and will be payable, along with the principal amount, on December 28, 2021. A lump-sum interest payment for one year is due on the December 28 Issuance Date and added to the principal balance and payable on the maturity date of the December 28 Note or upon acceleration or by prepayment or otherwise, notwithstanding the number of days which the principal is outstanding. Principal payments shall be made in 6 installments each in the amount of $56,000 commencing 180 days following the Issue Date (as defined in the Note) and continuing thereafter each 30 days for 5 months. During the year ended December 31, 2020, the Company recorded debt discount of $300,000 related to the December 28 Note. Amortization of the debt discount is recorded as interest expense and a total of $2,466 was amortized during the year ended December 31, 2020. The Company has a total outstanding principal balance of $300,000 as of December 31, 2020. Provided that an event of default under the December 28 Note has not occurred, the Company may prepay in whole or in part the amounts outstanding under the December 28 Note without a prepayment penalty. The December 28 Note contains customary events of default which entitle the investor, among other things, to accelerate the due date of the unpaid principal amount of, and all accrued and unpaid interest on, the December 28 Note. Upon an event of default, interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. The December 28 Note further contains monetary penalties in the event of certain events of default or breaches. The December Warrants each have an exercise price of $1.20, subject to customary adjustments, and may be exercised at any time until the three-year anniversary of the December Warrants; provided, however, in the event the Company repays the December 28 Note in its entirety on or prior to the maturity date of the December 28 Note, Warrant B shall automatically expire and may only be exercised in the event it does not so automatically expire. The December Warrants include a cashless exercise provision as set forth therein. Derivative Accounting for the December 28, 2020 Note The Company evaluated the terms and conditions of the December 28, 2020 Note and the accompanying December Warrants under the guidance of ASC 815. Certain of the Company’s outstanding warrants are treated as derivative liabilities for accounting purposes under ASC 815 due to insufficient authorized shares to settle these outstanding contracts, or due to other rights connected with these contracts, such as registration rights. In the case of insufficient authorized share capital available to fully settle outstanding contracts, the Company utilizes the issuance date sequencing method to reclassify outstanding contracts as derivative instruments. These instruments do not trade in an active securities market. As a result, the December Warrants are treated as a derivative liability. (see Note 7)

Derivative Liabilities

Derivative Liabilities	12 Months Ended
	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE LIABILITIES	NOTE 7 – DERIVATIVE LIABILITIES The Company evaluated the terms and conditions of the Notes and Convertible Notes Payable (see Notes 5 and 6) and pursuant to ASC 815-15 Embedded Derivatives, certain conversion options and outstanding warrants were recorded as derivative liabilities on the issuance date and revalued at each reporting period. The table below provides a summary of the changes in fair value, including net transfers in and/or out of all financial liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the year ended December 31, 2020: Amount Balance on December 31, 2019 $ - Issuances to debt discount 1,330,752 Issuances to interest expense 2,513,323 Net extinguishment 79,621 Change in fair value of derivative liabilities (801,801 ) Change in fair value of warrant liabilities (558,953 ) Balance on December 31, 2020 $ 2,562,942 The fair value of the derivative conversion features and warrant liabilities as of December 31, 2020 were calculated using a Monte-Carlo option model valued with the following assumptions: December 31, Dividend yield 0 % Expected volatility 46.4% - 82.2 % Risk free interest rate 0.05% - 0.36 % Contractual terms (in years) 0.08 - 4.30 Conversion/Exercise price $ 0.80 - $1.28

Other Liabilities

Other Liabilities	12 Months Ended
	Dec. 31, 2020
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
OTHER LIABILITIES	NOTE 8 – OTHER LIABILITIES In 2016, the Company recorded a liability in connection with the sale of two Electroencephalograms (“EEG”) machines as it provided a guarantee to the customer’s financing company (See Note 2). In June 2017, the customer defaulted on its payments and an additional $19,107 was booked as a liability and recognized as a loss on the sale of the assets for interest and some taxes related to the transaction. As of December 31, 2020 and December 31, 2019, total liability to the financing company reflected in Other Liabilities is $4,595 and $6,377, respectively. The Company did not make payments in the current quarter and are in discussion as to future payments since the equipment was not returned as per the agreement.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 9 – RELATED PARTY TRANSACTIONS During the year ended December 31, 2018, an entity controlled by Mr. Vadim Sakharov, a former director and executive officer of the Company, provided a $50,000 non-interest-bearing, no-term loan to the Company. An additional $5,530 of non-interest bearing no-term proceeds were loaned to the Company during the year ended December 31, 2019. As of December 31, 2020, and December 31, 2019, the balance was $55,530 and $55,530, respectively. During the years ended December 31, 2020 and 2019, the Company purchased an aggregate of $406,187 and $386,421 of medical devices for resale and distribution from Neurotech, a company that Mr. Sakharov, a former director and executive officer of the Company, is a shareholder and executive manager. During the years ended December 31, 2020 and 2019, the Company had expenses related to research and development costs of $26,920 and $50,713, respectively, to an entity controlled by Mr. Sakharov, a former director and executive officer of the Company. During the years ended December 31, 2020 and 2019, the Company had expenses related to sales and marketing costs of $53,578 and $0, respectively, to an entity controlled by Mr. Sakharov, a former director and executive officer of the Company. During the year ended December 31, 2019, an affiliate of Boris Goldstein, the Company’s Chairman of the Board, provided an aggregate total of $50,000, in a non-interest-bearing, no-term loan to the Company. As of December 31, 2020 and 2019, the balance was $50,000 and $50,000, respectively. On September 1, 2018, the Company entered into a sublease agreement with a company controlled by the Company’s Chairman, whereby the Company makes payments to the related party for shared office space. This lease was terminated on March 31, 2019. For the years ended December 31, 2020 and 2019, the Company made approximately $0 and $4,900, respectively, in rent payments to the related party. During the year ended December 31, 2019, an affiliate of Nickolay Kukekov, a director of the Company, provided an aggregate total of $217,000 in non-interest-bearing, no-term loans to the Company. As of December 31, 2020 and 2019, the balance was $217,000 and $217,000, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 10 – INCOME TAXES The Company files corporate income tax returns in the United States (federal) and New York. The Company is subject to federal, state and local income tax examinations by tax authorities through inception. As of December 31, 2020 and 2019, the Company had federal and state net operating loss carry forwards of $9,252,000 and $3,617,000, respectively that may be offset against future taxable income which will begin to expire in 2036 through 2040. There was a foreign provision for income tax during the year ended December 31, 2020. The tax effects of temporary differences which give rise to deferred tax assets (liabilities) are summarized as follows: For the Years Ended 2020 2019 Net operating loss carry forwards $ 2,596,740 $ 1,016,339 Stock based compensation 12,089 3,596 Depreciation 304 (22 ) Valuation allowance (2,609,133 ) (1,019,913 ) Net Deferred Tax Asset $ - $ - In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Deferred tax assets consist primarily of the tax effect of NOL carry-forwards. The Company has provided a full valuation allowance on the deferred tax assets because of the uncertainty regarding its realizability. Reconciliation of the statutory federal income tax to the Company’s effective tax: For the Years Ended December 31, 2020 2019 % % Statutory federal tax rate 21.00 % 21.00 % State taxes, net of federal benefit 9.39 % 6.99 % Derivative revaluation 6.67 % % Other 0.04 % % Valuation allowance -37.09 % -27.70 % Provision for income taxes 0.00 % 0.30 % The Company’s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the statement of operations. As of December 31, 2020 and 2019 the Company had no unrecognized tax benefits. There were no changes in the Company’s unrecognized tax benefits during the years ended December 31, 2020 and 2019. The Company did not recognize any interest or penalties during fiscal 2020 or 2019 related to unrecognized tax benefits. All tax years remain open to examination for federal income tax purposes and by other major taxing jurisdictions to which the Company is subject.

Leases

Leases	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
LEASES	NOTE 11 – LEASES The Company has inventoried all leases where the Company is a lessee as of the initial date of application and has examined other contracts with suppliers, vendors, customers and other outside parties to identify whether such contracts contain an embedded lease as defined under the new guidance. The Company’s lease population comprises lease for corporate office space and a warehouse that are year-to-year basis with monthly rent ranging from approximately $150 to $3,200 and qualify under the practical expedient of short-term leases. The Company does not have exclusive rights of control to any assets in the customer and vendor contracts reviews and does not have any financing leases as of the date of adoption of ASC 842. Beginning January 1, 2020, the Company entered into a 12-month lease agreement ending December 31, 2020, with a third party in Russia. The Company is paying rent at a rate of 17,900 Rubles ($240) per month. Beginning June 1, 2019, the Company entered into a 10-month lease agreement ending September 30, 2020 with a third party in Russia. The Company is paid rent at a rate of 12,000 Rubles ($161) per month. Additionally, the Company also rents a warehouse. Beginning December 1, 2018, the Company entered into a 6-month warehouse rental agreement for $2,980 per month. The lease was renewed on June 1, 2019 for an additional year ending May 31, 2020, for $3,171 per month. The Company leased the warehouse for an additional three months and left the premises in the third quarter of 2020. Total rent expense for the year ended December 31, 2020 and 2019 was $38,870 and $85,771, respectively. The Company has one lease agreement with terms up to 2 years for the lease of office space. The assets and liabilities from operating leases are recognized at the commencement date based on the present value of remaining lease payments over the lease term using the Company’s secured incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet. The Company’s operating lease does not provide an implicit rate that can readily be determined. Therefore, we use a discount rate based on our incremental borrowing rate, which is determined using the interest rate of our debt as of July 1, 2020. The Company’s weighted-average remaining lease term relating to its operating leases is 1.67 years, with a weighted-average discount rate of 12%. The Company incurred lease expense for its operating leases of $23,278 and $0 which was included in “General and administrative expenses,” for the year ended December 31, 2020 and 2019, respectively. The Company had operating cash flows used in operating leases of $18,272 for the year ended December 31, 2020. The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of December 31, 2020. Maturity of Lease Liability 2021 48,334 2022 32,699 Total undiscounted operating lease payments $ 81,033 Less: Imputed interest (7,964 ) Total operating lease liabilities 73,069 Less: Current portion of operating lease (41,793 ) Long-term portion of operating lease $ 31,276 At December 31, 2019, the operating lease right of use asset was $0. Supplemental balance sheet information related to the lease as of December 31, 2020 was: Operating lease right-of-use asset $ 69,632 Lease liability, current portion 41,793 Lease liability, long-term 31,276 Total operating lease liability $ 73,069 Weighted average remaining lease term (months) 20 Weighted average discount rate 12 %

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 12 – STOCKHOLDERS’ DEFICIT Preferred Stock The Company has authorized 10,000,000 shares of undesignated preferred stock with a $0.001 par value. As of December 31, 2020, no preferred shares have been issued and these shares are considered blank check preferred shares with no terms, limitations, or rights associated with them. Common Stock The Company has authorized 200,000,000 shares of common stock with a $0.001 par value per share. The holders of common stock are entitled to one vote for each share of common stock held at the time of vote. As of December 31, 2020, the Company has deemed 19,628,258 shares outstanding or deemed outstanding. Shares Issued for Services On December 4, 2019, the Company entered into an agreement with an advisor to memorialize certain services rendered to the Company. Pursuant to the terms of the agreement, in consideration for those services, the Company issued the advisor 75,000 shares of common stock. The shares were valued at $0.12 per share or $9,150. On October 1, 2019, the Company entered into a three-month agreement with an advisor for consulting services. Pursuant to the agreement, the Company shall pay the advisor 4,000 shares of common stock a month. As of December 31, 2019, the Company has issued 4,000 shares at a value of $0.12 per share or $488. The agreement was terminated on October 31, 2019. On October 7, 2019, the Company entered into a three-month agreement with an advisor for consulting services. Pursuant to the agreement, the Company shall pay the advisor 7,500 shares of common stock a month. As of December 31, 2019, the Company has issued 22,500 shares at a value of $0.12 per share or $2,745. On August 8, 2018, the Company entered into a one-year agreement with an advisor for consulting services, as extended for an additional one-year period. Pursuant to the agreement, as amended, the Company has the right to pay $5,000 or issue the advisor a maximum of 6,667 shares of common stock on a quarterly basis, beginning the quarter ended December 31, 2018. The Company elected to issue 26,668 shares for the services provided during the year ended December 31, 2019 at an average value of $0.08 per share or $1,653. The Company elected to issue 9,899 shares for the services provided during the year ended December 31, 2020 at an average value of $1.52 per share or $15,000. On August 28, 2018, the Company entered into a one-year agreement with an advisor for consulting services, as extended for an additional one-year period. Pursuant to the agreement, as amended, the Company has the right to pay $5,000 or issue the advisor a maximum of 6,667 shares of common stock on a quarterly basis, beginning the quarter ended December 31, 2018. The Company elected to issue 26,668 shares for the services provided during the year ended December 31, 2019 at an average value of $0.08 per share or $1,653. The Company elected to issue 9,899 shares for the services provided during the year ended December 31, 2020 at an average value of $1.52 per share or $15,000. On September 1, 2019, the Company entered into a four-month agreement with an advisor for consulting services. Pursuant to the agreement, the Company shall pay the advisor 5,000 shares of common stock a month. As of December 31, 2019, the Company has issued 20,000 shares for services provided by the advisor at an average value of $0.10 per share or $2,000. On June 1, 2020 the Company entered into an additional four-month agreement with an advisor for consulting services. Pursuant to the agreement, the Company shall pay the advisor 7,000 shares of common stock a month. As of December 31, 2020, the Company has issued 28,000 shares for services provided by the advisor at an average value of $1.14 per share or $32,025. On November 13, 2020, the Company entered into a six-month agreement with a consultant to provide services to the Company. As compensation for such services, the Company has agreed to pay the consultant $6,000 in cash and allowed the consultant to purchase 100,000 shares of the Company’s restricted common stock for a total purchase price of $500. The fair value per share on the November 13, 2020 issuance date was $1.00 or $100,000. During 2020 the Company recorded $26,019 of consulting expenses. On October 15, 2020, the Company granted to a newly-hired non-executive officer of the Company 292,174 restricted shares under the Company’s 2018 Equity Incentive Plan, which vest quarterly in equal amounts commencing January 15, 2021 and ending January 15, 2022. The shares were valued as of the date of the grant at a fair value of $1.67 per share or $487,931, which will be amortized over the vesting period. As of December 31, 2020, the Company has recorded $45,706 in stock-based compensation. December 31, 2019 Securities Purchase Agreement During the year ended December 31, 2019, in connection with the Securities Purchase Agreement (see Note 5), the company issued 100,000 warrants to a third party. The warrants were initially accounted for as a discount to the December 31, 2019 convertible note and therefore fair-valued using the Monte Carlo model. On March 18, 2020 upon the Initial Public Offering and the existence of a market for the common stock, the warrants were considered a derivative liability and as such are presented at every reporting period at fair value. Upon inception, the warrants were evaluated with the following assumptions: - The stock price of $0.1208 would fluctuate with an annual volatility - The projected volatility curve was based on historical volatility of comparable companies for the valuation period and the remaining term of the warrants. The volatility used was 85.2%. - The stock price projection was modeled such that it follows a geometric Brownian motion with constant drift and a constant volatility, starting with market prices. - The warrants are exercised at maturity, December 31, 2024, by the holder if they are in the money based on the adjusted exercise price (adjusted for full ratchet reset events). - The warrants have a fixed $1.25 exercise price subject to full ratchet reset provisions. Capital raising events triggering a reset to 100% of the projected stock price (no discount to the market) are projected for the warrants on 6/30/20, 6/30/21 and 6/30/22. - The cash flows are discounted to net present values using risk free rates. Discount rates were based on risk free rates in effect based on the remaining term. As a result of certain terms granted as part of the issuance of the December 28 notes (see Note 6) the abovementioned warrants were reset from 100,000 to 125,000, and the exercise price was adjusted from $1.25 to $1.00. Convertible Grid Notes On April 21, 2020, in connection with the issuance of the Grid Notes (see Note 5), the company issued 1,500,000 warrants (the Grid Warrants) to a third party. The Grid Warrants were accounted for as a derivative liability and are presented at every reporting period at fair value. At issuance the Grid Warrants were fair-valued using the Monte Carlo model with the following assumptions: - Stock price of $1.00 - The projected volatility curve was based on historical volatility of comparable companies for the valuation period and the remaining term of the warrants. The volatility used was 72.5%. - The stock price projection was modeled such that it follows a geometric Brownian motion with constant drift and a constant volatility, starting with market prices. - The warrants are exercisable at any time commencing 18 months from the issuance date and expire on April 21, 2025. - The warrants have a fixed $0.80 exercise. - The cash flows are discounted to net present values using risk free rates. Discount rates were based on risk free rates in effect based on the remaining term. September 22, 2020 Securities Purchase Agreement On September 22, 2020, in connection with the September Purchase Agreement (see Note 5), the company issued 1,411,764 warrants (the September Warrants) to a third party. The September Warrants were accounted for as a derivative liability and are presented at every reporting period at fair value. At issuance the September Warrants were fair-valued using the Monte Carlo model with the following assumptions: - Stock price of $1.25 - The projected volatility curve was based on historical volatility of comparable companies for the valuation period and the remaining term of the warrants. The volatility used was 84.0%. - The stock price projection was modeled such that it follows a geometric Brownian motion with constant drift and a constant volatility, starting with market prices. - The warrants are may be exercised at any time until the three year anniversary of the Warrants; provided, however, in the event the Company repays the September 22 Note in its entirety on or prior to the Maturity Date, 705,882 September Warrants shall automatically expire and may only be exercised in the event it does not so automatically expire. - The warrants have a fixed $1.28 exercise price subject to full ratchet reset provisions. Capital raising events triggering a reset to 100% of the projected stock price (no discount to the market) are projected for the warrants on 6/30/20, 6/30/21 and 6/30/22. - The cash flows are discounted to net present values using risk free rates. Discount rates were based on risk free rates in effect based on the remaining term. As a result of certain terms granted as part of the issuance of the December 28 notes (see Note 6) the abovementioned warrants were reset from 1,411,764 to 1,505,882, and the exercise price was adjusted from $1.28 to $1.20. The following table summarized the warrant activity for the years ended December 31, 2020 and 2019: Warrants Number Weighted Weighted Aggregate Balance Outstanding, December 31, 2018 402,250 $ 0.40 4.72 $ - Granted 100,00 $ 1.25 5.00 - Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2019 502,250 $ 0.57 3.98 $ 201,125 Granted 3,530,882 1.02 3.90 150,000 Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2020 4,033,132 $ 0.97 3.39 $ 351,125 Exercisable, December 31, 2020 2,533,132 $ 1.06 2.84 $ 201,125 Equity Incentive Plan As of September 21, 2018, the Company’s board of directors adopted, and stockholders approved the 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan has a 10-year term, which terminates on the day prior to the 10 th On January 14, 2019, the Board of Directors approved the issuance of options to purchase an aggregate of 800,000 and 200,000 shares of common stock to Boris Goldstein and Vadim Sakharov (a former director and executive officer of the Company), respectively. The options have an exercise price of $0.75 per share which will vest over a 24-month period as follows: 25% (or 200,000 and 50,000, respectively) shall vest six months after the grant date with the remaining options will vest on a monthly basis at a rate of 1/24 th On January 30, 2020, the Board of Directors approved the issuance of options to purchase an aggregate of 800,000 shares of common stock to Boris Goldstein. The options have an exercise price of $0.75 per share which will vest ratably on a quarterly basis over a two year period. The options will expire on January 30, 2029. The aggregate fair value of $51,757 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life 10 years, (ii) volatility of 76%, (iii) risk free rate of 1.57% (iv) dividend rate of zero, (v) stock price of $0.12, and (vi) exercise price of $0.75. The expense will be amortized over the vesting period and a total of $23,790 was recorded during the year ended December 31, 2020. The following table summarized the option activity for the years ended December 31, 2020 and 2019: Options Number of Weighted Weighted Aggregate Balance Outstanding, December 31, 2018 $ $ - Granted 1,800,00 $ 0.75 10.00 - Forfeited (800,000 ) - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2019 1,000,000 $ 0.75 9.05 $ 150,000 Granted 800,000 0.75 10.00 120,000 Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2020 1,800,000 $ 0.75 8.51 $ 270,000 Exercisable, December 31, 2020 1,400,000 $ 0.75 8.34 $ 210,000 For future periods, the remaining value of the stock options totaling approximately $28,230 will be amortized into the statement of operations consistent with the period for which the services will be rendered.

Concentrations

Concentrations	12 Months Ended
	Dec. 31, 2020
Risks and Uncertainties [Abstract]
CONCENTRATIONS	NOTE 13 – CONCENTRATIONS In the years ending December 31, 2020 and 2019, respectively, the Company purchased 99.28% and 99.84% of its medical devices for resale and distribution from Neurotech, a company that Vadim Sakharov, a former director and executive officer of the Company, is a shareholder and executive manager.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 14 – COMMITMENTS AND CONTINGENCIES Financial Advisory Agreement On February 1, 2017, the Company entered into a one-year agreement with a third party to act as the Company’s exclusive financial advisor (the “Financial Advisor”). In consideration for services, the Company will pay a cash fee equal to 8% of the total amount of capital received by the Company from institutions and 10% of the total amount of capital received by the Company from retail. With the exception of the Bridge Private Placement Transaction, the Company will also pay a cash amount, representing a non-accountable expense allowance payable immediately upon closing of a financing equal to 3% of the aggregate gross proceeds raised in the transactions from retail. In addition to the cash consideration, the Company will also issue warrants to purchase common stock to the Financial Advisor in an amount equal to 10% of the number of shares of common stock purchased by the investors and that the investors obtain a right to acquire through purchase, conversion or exercise of convertible securities issued by the Company. Those warrants will be immediately exercisable at the price per share at which the investor can acquire the common stock. On February 5, 2018, the agreement was amended to extend the exclusivity period another 12 months through February 1, 2019, all other terms and conditions of the agreement remained the same.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 15 – SUBSEQUENT EVENTS In accordance with ASC 855 “Subsequent Events,” Company management reviewed all material events through the date this report was issued and the following subsequent events took place. Loan Extensions Subsequent to the balance sheet date, the January 18, 2019, February 5, 2019 and July 23, 2019 convertible notes (see Note 5) were extended to January 18, 2022, February 5, 2022 and February 21, 2022, respectively. On February 8, 2021, the Company entered into a third Allonge to the Convertible Note (see Note 5) which amended the Note by, among other things, extending the maturity date of the loan until May 1, 2021. As consideration for the allonge, the original principal amount was increased by ten percent, and the Company agreed to issue 50,000 shares of its common stock to the investor. February 8, 2021 Loan On February 8, 2021, the Company signed a loan agreement in the amount on $500,000 pursuant to which the Company would enter into a business combination with the lender subject to the terms and conditions defined in the agreement. The loan bears interest of 10% and matures upon the earlier of 6 months or the date that the business combination becomes effective. In the case of a business combination becoming effective, the loan shall convert immediately into or be credited towards such transaction. Stock Option Agreements On January 26, 2021 the Company granted a director 16,779 fully vested stock options. On February 11, 2021, the Company granted certain employees options to purchase an aggregate number of 125,000 shares of common stock, exercisable at $1.50 per share which will vest over a 24-month period as follows: 25% shall vest six months after the grant date with the remaining options will vest on a monthly basis at a rate of 1/24 th Share Offering The Company is currently involved in a Regulation A+ share offering pursuant to which the Company is offering up to a maximum of 1,111,111 units, with each unit consisting of five shares of common stock, par value $0.001, and a warrant to purchase one share of common stock, par value $0.001, at an offering price of $9.00 per unit or $1.80 per share of common stock, for a maximum aggregate offering of $10,000,000. Loan Conversion On March 16, 2021, the Company received a Notice of Conversion from the holder of the Diamond Note, electing to convert $20,000 of outstanding principal and $871 of outstanding interest into 27,828 common shares at an applicable conversion price of $0.75 per share. This conversion triggered certain anti-dilution provisions of the Note (See note 5) and as a result, the conversion price of the Note was reduced to $0.75, and the warrant amount was reset to 166,667 with an exercise price of $0.75 per share. Financial Services Agreement On February 25, 2021, the Company signed a contract with a financial services provider in connections with future potential transactions. At the closing of the potential transactions, the financial services provider will be entitled to fees in the form of cash, warrants and shares of common stock dependent on the amount of funds raised as part of the transaction.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with GAAP.
Principles of Consolidation	Principles of Consolidation The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (“ASC 810”). The consolidated financial statements include the accounts of the Company and its subsidiaries, MemoryMD and MemoryMD - Russia. The operations of the newly formed 100% wholly owned subsidiaries, MemoryMD – Russia and MemoryMD Europe, are included beginning April 1, 2019 and July 1, 2019, respectively. All significant consolidated transactions and balances have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the useful life of property and equipment and assumptions used in the valuation of options and warrants.
The Effects of COVID-19	The Effects of COVID-19 The World Health Organization (WHO) declared the coronavirus outbreak a pandemic on January 30, 2020. Since the outbreak in China in December 2019, COVID-19 has expanded its impact to Europe, where all of our operations reside, as well as our employees, suppliers and customers. While the disruption is currently expected to be temporary, there is considerable uncertainty around the duration of the closings and shelter-in-place orders and the ultimate impact of governmental initiatives. However, the financial impact and duration cannot be reasonably estimated at this time.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At December 31, 2020 and December 31, 2019, the Company had no cash equivalents. The Company’s cash is held with financial institutions, and the account balances may, at times, exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit. Accounts are insured by the FDIC up to $250,000 per financial institution. The Company has not experienced any losses in such accounts with these financial institutions. As of December 31, 2020 and December 31, 2019, the Company had $22,856 and $11,436, respectively, in excess over the FDIC insurance limit.
Accounts Receivable	Accounts Receivable Accounts receivable are carried at net realizable value and are reviewed for collectibility on an ongoing basis. For the years ended December 31, 2020 and 2019, the Company did not recognize any allowances for doubtful accounts.
Inventory	Inventory Inventory consists of finished goods that are valued at lower of cost or market using the weighted average method. As of December 31, 2020, and December 31, 2019, the Company had inventory totaling $1,461 and $0, respectively.
Property and Equipment	Property and Equipment Property and equipment are recorded at cost, less depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Expenditures for repair and maintenance are charged to operations as incurred. Property and equipment consisted of computer equipment, with an estimated useful life of three years.
Convertible Notes Payable	Convertible Notes Payable The Company has issued convertible notes, which contain variable conversion features, whereby the outstanding principal and accrued interest automatically convert into common shares at a fixed price which may be a discount to the common stock at the time of conversion. Some of the conversion features of these notes are contingent upon future events, whereby, the holder agreed not to convert until the contingent future event has occurred.
Derivative Instruments	Derivative Instruments The Company evaluates its convertible notes and warrants to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815. The result of this accounting treatment is that the fair value of the embedded derivative is recorded as a liability and marked-to-market each balance sheet date. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statements of operations as other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. The Company utilizes the Monte Carlo Method that values the liability of the debt conversion feature, derivative financial instruments and derivative warrants in cases where there may be multiple embedded features or the features of the bifurcated derivatives may be so complex that a Black-Scholes valuation does not consider all of the terms of the instrument. Therefore, the fair value may not be appropriately captured by simple models. The Monte Carlo technique applied generates many possible (but random) price paths for the underlying (or underlyings) via simulation, and then calculates the associated payment value of the derivative features. The price of the underlying common stock is modeled such that it follows a geometric Brownian motion with constant drift, and constant volatility. The stock price is determined by a random sampling from a normal distribution. Since the underlying random process is the same, for enough price paths, the value of derivative is derived from path dependent scenarios and outcomes. The Company also applied a Black Scholes (“BSM”) analysis for the tainted notes and tainted warrants with simple fixed conversion and exercise prices. The BSM derivative valuation assumes these tainted securities are held till maturity. From time to time, certain of the Company’s embedded conversion features on debt and outstanding warrants have been treated as derivative liabilities for accounting purposes under ASC 815 due to insufficient authorized shares to fully settle conversion features of the instruments if exercised. In this case, the Company utilized the latest inception date sequencing method to reclassify outstanding instruments as derivative instruments. These contracts were recognized at fair value with changes in fair value recognized in earnings until such time as the conditions giving rise to such derivative liability classification were settled.
Leases	Leases In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires lessees to recognize most leases on their balance sheets as a right-of-use asset with a corresponding lease liability. Lessor accounting under the standard is substantially unchanged. Additional qualitative and quantitative disclosures are also required. The Company adopted the standard effective January 1, 2019 using the cumulative-effect adjustment transition method, which applies the provisions of the standard at the effective date without adjusting the comparative periods presented. The Company adopted the following practical expedients and elected the following accounting policies related to this standard update: ● Short-term lease accounting policy election allowing lessees to not recognize right-of-use assets and liabilities for leases with a term of 12 months or less. ● The option to not separate lease and non-lease components for certain equipment lease asset categories such as freight car, vehicles and work equipment. As a result of the above, the adoption of ASC 842 did not have a material effect on the consolidated financial statements.
Revenue Recognition	Revenue Recognition On January 1, 2018, the Company adopted ASC Topic 606 Revenue from Contracts with Customers. This guidance requires an entity to recognize revenue by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Once the steps are met, revenue is recognized, generally upon receiving a letter of acceptance from the customer. There has been no material effect on the Company’s financial statements as a result of adopting Topic 606. The Company recognizes revenue from the sale of NeuroCaps, as well as revenue from the sale of goods purchased through manufacturers of medical devices. Primarily all revenue for the years ended December 31, 2020 and 2019 is from the sale of medical devices purchased from Neurotech, a related party.
Research and Development	Research and Development The Company expenses all research and development costs as they are incurred. Research and development includes expenditures in connection with in-house research and development salaries and staff costs, application and filing for regulatory approval of proposed products, regulatory and scientific consulting fees, as well as contract research, data collection, and monitoring, related to the research and development of the cloud infrastructure, data imaging, and proprietary products and technology. Research and development costs recognized in the statement of operations for the years ended December 31, 2020 and 2019 were $275,926 and $103,616, respectively.
Sales and Marketing	Sales and Marketing Advertising and marketing costs are expensed as incurred. Advertising and marketing costs recognized in the statement of operations for the years ended December 31, 2020 and 2019 were $244,774 and $95,165, respectively.
Stock-based Compensation	Stock-based Compensation The Company measures and recognizes compensation expense for all stock-based payments at fair value over the requisite service period. The Company uses the Black-Scholes option pricing model to determine the weighted average fair value of options and warrants. Equity-based compensation expense is recorded in administrative expenses based on the classification of the employee or vendor. The determination of fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as by assumptions regarding a number of subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors.
Basic and Diluted Net Loss Per Common Share	Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. In the years ended December 31, 2020 and 2019, 7,415,040 and 1,502,250, respectively, of anti-dilutive securities were excluded from the computation.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments are measured and recorded at fair value based on inputs and assumptions that market participants would use in pricing an asset or a liability. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, management considers the principal or most advantageous market in which the Company would transact, and also considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance. Fair value is determined for assets and liabilities using a three-tiered value hierarchy into which these assets and liabilities are grouped based upon significant inputs as follows: ● Level 1 - Quoted prices in active markets for identical assets or liabilities. ● Level 2 - Observable inputs, other than Level 1 prices, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. ● Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. When a determination is made to classify a financial instrument within Level 3, the determination is based upon the lack of significance of the observable parameters to the overall fair value measurement. However, the fair value determination for Level 3 financial instruments may consider some observable market inputs. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy. The carrying values of cash, prepaid expenses and other current assets, convertible notes, accounts payable, loans payable and due to others approximate fair value due to the short-term nature of these items. The Company did not have any Level 1 or Level 2 assets or liabilities as of December 31, 2020 and the Company did not have any other Level 1, Level 2 or Level 3 assets or liabilities as of December 31, 2019. Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the consolidated balance sheet as of December 31, 2020. Liabilities Amounts at Level 1 Level 2 Level 3 Derivative liability – conversion feature $ 345,708 $ - $ - $ 345,708 Derivative liability - warrants 2,217,234 - - 2,217,234 Total $ 2,562,942 $ - $ - $ 2,562,942
Income Taxes	Income Taxes The Company accounts for income taxes using the asset-and-liability method in accordance with ASC Topic 740, “Income Taxes”. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is recognized in the period that includes the enactment date. A valuation allowance is recorded if it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized in future periods. The Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely-than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties related to tax positions in income tax expense. As of December 31, 2020, and December 31, 2019, the Company had no unrecognized uncertain income tax positions.
Recent Issued Accounting Pronouncements	Recent Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on the Company’s financial position or results of operations upon adoption. In June 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2016-13, “Measurement of Credit Losses on Financial Instruments,” which requires measurement and recognition of expected credit losses at the point a loss is probable to occur, rather than expected to occur, which will generally result in earlier recognition of allowances for credit losses. The new guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted ASU 2016-13 in the first quarter of 2020 and the adoption did not have a material impact on its condensed consolidated financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of financial liabilities measured at fair value	Liabilities Amounts at Level 1 Level 2 Level 3 Derivative liability – conversion feature $ 345,708 $ - $ - $ 345,708 Derivative liability - warrants 2,217,234 - - 2,217,234 Total $ 2,562,942 $ - $ - $ 2,562,942

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	December 31, 2020 December 31, 2019 Computer equipment $ 4,105 $ 4,105 Less: Accumulated depreciation (3,807 ) (2,431 ) Total $ 302 $ 1,674

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of financial liabilities measured at fair value on a recurring basis using significant unobservable inputs	Amount Balance on December 31, 2019 $ - Issuances to debt discount 1,330,752 Issuances to interest expense 2,513,323 Net extinguishment 79,621 Change in fair value of derivative liabilities (801,801 ) Change in fair value of warrant liabilities (558,953 ) Balance on December 31, 2020 $ 2,562,942
Schedule of derivative conversion features and warrant liabilities	December 31, Dividend yield 0 % Expected volatility 46.4% - 82.2 % Risk free interest rate 0.05% - 0.36 % Contractual terms (in years) 0.08 - 4.30 Conversion/Exercise price $ 0.80 - $1.28

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of deferred tax assets and liabilities	For the Years Ended 2020 2019 Net operating loss carry forwards $ 2,596,740 $ 1,016,339 Stock based compensation 12,089 3,596 Depreciation 304 (22 ) Valuation allowance (2,609,133 ) (1,019,913 ) Net Deferred Tax Asset $ - $ -
Schedule of reconciliation of the statutory federal income tax	For the Years Ended December 31, 2020 2019 % % Statutory federal tax rate 21.00 % 21.00 % State taxes, net of federal benefit 9.39 % 6.99 % Derivative revaluation 6.67 % % Other 0.04 % % Valuation allowance -37.09 % -27.70 % Provision for income taxes 0.00 % 0.30 %

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Schedule of maturity of lease liability	Maturity of Lease Liability 2021 48,334 2022 32,699 Total undiscounted operating lease payments $ 81,033 Less: Imputed interest (7,964 ) Total operating lease liabilities 73,069 Less: Current portion of operating lease (41,793 ) Long-term portion of operating lease $ 31,276
Schedule of supplemental balance sheet information related to the lease	Operating lease right-of-use asset $ 69,632 Lease liability, current portion 41,793 Lease liability, long-term 31,276 Total operating lease liability $ 73,069 Weighted average remaining lease term (months) 20 Weighted average discount rate 12 %

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	12 Months Ended
	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Schedule of warrant activity	Warrants Number Weighted Weighted Aggregate Balance Outstanding, December 31, 2018 402,250 $ 0.40 4.72 $ - Granted 100,00 $ 1.25 5.00 - Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2019 502,250 $ 0.57 3.98 $ 201,125 Granted 3,530,882 1.02 3.90 150,000 Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2020 4,033,132 $ 0.97 3.39 $ 351,125 Exercisable, December 31, 2020 2,533,132 $ 1.06 2.84 $ 201,125
Schedule of option activity	Options Number of Weighted Weighted Aggregate Balance Outstanding, December 31, 2018 $ $ - Granted 1,800,00 $ 0.75 10.00 - Forfeited (800,000 ) - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2019 1,000,000 $ 0.75 9.05 $ 150,000 Granted 800,000 0.75 10.00 120,000 Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2020 1,800,000 $ 0.75 8.51 $ 270,000 Exercisable, December 31, 2020 1,400,000 $ 0.75 8.34 $ 210,000

Organization and Nature of Op_2

Organization and Nature of Operations (Details) - USD ($)	Sep. 21, 2018	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Sep. 18, 2018
Organization and Nature of Operations (Textual)
Stock repurchase program, number of shares authorized to be repurchased	6,495,000
Cancellation of common stock, shares (in Dollars)				$ 6,375,000
Stock repurchase program, remaining number of shares authorized to be repurchased				120,000
Business acquisition, equity interest issued or issuable, number of shares		13,421,752
Common stock, shares authorized		200,000,000	200,000,000
Preferred stock, shares authorized		10,000,000	10,000,000		10,000,000
Minimum [Member]
Organization and Nature of Operations (Textual)
Common stock, shares authorized					50,000,000
Maximum [Member]
Organization and Nature of Operations (Textual)
Common stock, shares authorized					200,000,000
Memory MD [Member]
Organization and Nature of Operations (Textual)
Equity method investment, ownership percentage	100.00%
Memory MD [Member] | Principal and Accrued Interest of Promissory Note Issued by Memory MD [Member] | Automatic Conversion At Closing [Member]
Organization and Nature of Operations (Textual)
Debt conversion, converted instrument, shares issued	4,083,252
Debt conversion, original debt, amount (in Dollars)	$ 1,507,000
Memory MD [Member] | Principal and Accrued Interest of Promissory Note Issued by Memory MD [Member] | Automatic Conversion Immediately Subsequent To Closing [Member]
Organization and Nature of Operations (Textual)
Debt conversion, converted instrument, shares issued	1,604,378
Debt conversion, original debt, amount (in Dollars)	$ 640,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Summary of Significant Accounting Policies (Textual)
Cash, FDIC insured amount	$ 250,000
Cash, uninsured amount	22,856	$ 11,436
Inventory	$ 1,461	0
Estimated useful life	3 years
Assets or Liabilities that Relate to Transferor's Continuing Involvement in Securitized or Asset-backed Financing Assets, Policy [Policy Text Block]	842
Recognition of Asset and Liability for Lease of Acquiree [Policy Text Block]	12 months
Research and development expense	$ 275,926	103,616
Advertising and marketing costs	$ 244,774	$ 95,165
Anti-dilutive securities excluded from computation (in Shares)	7,415,040	1,502,250
Income tax benefit, percentage	50.00%
Memory MD [Member]
Summary of Significant Accounting Policies (Textual)
Owned subsidiary, percentage	100.00%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of financial liabilities measured at fair value	12 Months Ended
	Dec. 31, 2020USD ($)
Summary of Significant Accounting Policies (Details) - Schedule of financial liabilities measured at fair value [Line Items]
Derivative liability – conversion feature	$ 345,708
Derivative liability - warrants	2,217,234
Total	2,562,942
Fair Value, Inputs, Level 1 [Member]
Summary of Significant Accounting Policies (Details) - Schedule of financial liabilities measured at fair value [Line Items]
Derivative liability – conversion feature
Derivative liability - warrants
Total
Fair Value, Inputs, Level 2 [Member]
Summary of Significant Accounting Policies (Details) - Schedule of financial liabilities measured at fair value [Line Items]
Derivative liability – conversion feature
Derivative liability - warrants
Total
Fair Value, Inputs, Level 3 [Member]
Summary of Significant Accounting Policies (Details) - Schedule of financial liabilities measured at fair value [Line Items]
Derivative liability – conversion feature	345,708
Derivative liability - warrants	2,217,234
Total	$ 2,562,942

Going Concern (Details)

Going Concern (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Going Concern (Textual)
Revenues	$ 544,275	$ 489,202
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	4,284,785
Net cash used in operation activity	(1,173,409)	(854,726)
Working capital deficit	4,765,850
Stockholders' deficit	(4,796,824)	(895,532)	$ (53,972)
Accumulated deficit	$ (7,956,862)	$ (3,672,077)

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 1,372	$ 1,330

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of property and equipment - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Total	$ 302	$ 1,674
Less: Accumulated depreciation	(3,807)	(2,431)
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Total	$ 4,105	$ 4,105

Convertible Notes Payable (Deta

Convertible Notes Payable (Details) - USD ($)	Sep. 01, 2020	Aug. 05, 2020	Apr. 22, 2020	Apr. 21, 2020	Jul. 23, 2019	Feb. 05, 2019	Dec. 28, 2020	Oct. 29, 2020	Sep. 22, 2020	Feb. 28, 2020	Jan. 31, 2019	Jan. 18, 2019	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Mar. 18, 2020
Convertible Notes Payable (Textual)
Proceeds from convertible debt														$ 285,000	$ 50,000
Convertible notes payable, description											The notes bear interest at a fixed rate of 10% per annum, computed based on a 360-day year and mature on the earlier of one year from the date of issuance or the consummation of an equity or equity-linked round of financing of the Company in excess of $1,000,000 (“Qualified Financing”) or other event pursuant to which conversion shares are to be issued pursuant to the terms of the note.
Convertible debt maturity date, description										the Company and the holder of the January 18, 2019 convertible note agreed to extend the maturity date of the January 18, 2019 convertible note to January 18, 2021. On February 24, 2021, the January 18, 2019 convertible note was further extended to January 18, 2022. On February 28, 2020, the Company and the holder of the February 5, 2019 convertible note agreed to extend the maturity date of the February 5, 2019 convertible note to February 5, 2021. On February 24, 2021, the February 5, 2019 convertible note was further extended to February 5, 2022. On July 22, 2020 the Company and the holder of the July 23, 2019 convertible note agreed to extend the maturity date of July 23, 2020 to February 21, 2021.
Principle amount				$ 125,000
Warrant purchase shares (in Shares)				750,000
Warrant exercise price per share (in Dollars per share)				$ 0.80
Warrants fair value														2,217,234
Derivative liabilities														146,873
Agree to issue shares of common stock (in Shares)		50,000						50,000
Fair market value price		$ 75,000						$ 75,000
Debt extinguishment percentage		10.00%						10.00%
Principal and accrued interest written off		$ 297,000						$ 324,500
New debt amount		324,500						359,370
Net loss on extinguishment of debt		$ 176,467					$ 11,000	$ 115,524						(294,301)
Debt interest rate							12%
Convertible debt value							$ 2,310
Interest expense							11,000							6,996
Net loss on extinguishment of debt							$ 2,310							294,301
Investment Owned, Balance, Principal Amount														339,680
Accrued interest														33,000
Debt discount														300,000
Additional debt discount														$ 176,274
Exercise price (in Dollars per share)														$ 1
Advance cash			$ 25,000											$ 897,700	630,000
Principal amount														250,000
Debt discount														233,893
Amortization of debt discount														$ 159,917
Bear interest rate														12.00%
Accrued interest														$ 17,532
Outstanding principal balance														$ 250,000
Fixed interest percentage							12.00%
Debt interest rate														12.00%
December 31, 2019 Securities Purchase Agreement [Member]
Convertible Notes Payable (Textual)
Convertible notes payable, description														The unpaid outstanding principal amount and accrued and unpaid interest under the Note shall be convertible into shares of the Company’s common stock at any time at the option of the investor. The conversion price shall be equal to 80% multiplied by the price per share paid by the investors in the next capital raising transaction consummated by the Company in the amount of $1,000,000 or more (the “Qualified Financing”), subject to adjustments as provided in the Note. In the event the investor elects to convert the Note prior to a Qualified Financing, the conversion price shall be the effective exercise price per share from time to time pursuant to the Warrant. At any time prior to the maturity date of the Note, upon 10 business days’ notice to the investor, the Company shall have the right to pre-pay the entire remaining principal amount of the Note subject to the pre-payment terms contained in the Note.
Principle amount															$ 275,000
Warrant purchase shares (in Shares)															100,000
Purchase price received															$ 250,000
Original issue discount															$ 25,000
Interest charge in percentage															8.00%
Beneficial ownership percentage															4.99%
Outstanding balance percentage															130.00%
Conversion price redefined															65.00%
Warrant exercise price per share (in Dollars per share)															$ 1.25
Warrant term															5 years
Beneficial ownership percentage of warrant															9.99%
Warrants fair value															$ 130,768
Derivative liabilities																$ 255,899
Warrant derivative														$ 109,026
Debt discount															$ 155,768
Interest Expense, Debt														332,042
September 1, 2020 Securities Purchase Agreement [Member]
Convertible Notes Payable (Textual)
Convertible notes payable, description	The unpaid outstanding principal amount and accrued and unpaid interest under the September 1 Note shall be convertible into shares of common stock at any time on or after the September 1 Issuance Date at the option of the investor. The conversion price shall be equal to 60% of the lowest closing bid price for the common stock, subject to certain exceptions and adjustments contained in the September 1 Note, for the fifteen prior trading day period. From the September 1 Issuance Date until 180 days after the September 1 Issuance Date, upon 3 days’ notice to the investor, the Company shall have the right to pre-pay the entire remaining principal amount of the September 1 Note, subject to the pre-payment terms contained in the September 1 Note.
Outstanding principal balance														157,500
Issued and sold investor percentage	8.00%
Original principal amount	$ 157,500
Net amount received	142,500
Original issue discount	$ 15,000
Fixed interest percentage	8.00%
Debt discount														157,500
Total amortization														54,370
Accrued interest														6,471
Beneficial ownership limitation percentage	4.99%
Notice of investor percentage	9.90%
Default interest rate	24.00%
Principal amount percentage	150.00%
September 22, 2020 Securities Purchase Agreement [Member]
Convertible Notes Payable (Textual)
Convertible notes payable, description									A lump-sum interest payment for one year is due on the September 22 Issuance Date and added to the principal balance and payable on the maturity date of the September 22 Note or upon acceleration or by prepayment or otherwise, notwithstanding the number of days which the principal is outstanding. Principal payments shall be made in 6 installments each in the amount of $100,000 commencing 180 days following the applicable Issue Date (as defined in the Note) and continuing thereafter each 30 days for 5 months.
Original principal amount									$ 600,000
Fixed interest percentage									12.00%
Debt discount														600,000
Total amortization														105,815
Beneficial ownership limitation percentage									4.99%
Default interest rate									24.00%
Aggregate borrowed principal amount									$ 100,000
Purchase of aggregate common stock (in Shares)									1,411,764
Common stock commitment fee (in Shares)									705,882
Additional commitment fee									$ 705,882
Payment for certain fee														505,000
Total outstanding principal balance														$ 600,000
Exercise price (in Shares)									1.28
Warrant shares (in Shares)							1,505,882
September 22, 2020 Securities Purchase Agreement [Member]
Convertible Notes Payable (Textual)
Warrant exercise price (in Dollars per share)							$ 1.20
Convertible Notes Payable [Member] | Debt Instrument, Redemption, Period One [Member]
Convertible Notes Payable (Textual)
Debt offering amount											$ 500,000
Proceeds from convertible debt					$ 150,000	$ 130,000						$ 100,000
Convertible notes payable, description													the debt will be converted to new round stock based on the product of the outstanding principal and accrued interest multiplied by 1.35, then divided by the accrual per share price of the new round common stock. If a change of control occurs or if the Company completes a firmly underwritten public offering of its common stock prior to the Qualified Financing the notes would, at the election of the holders of a majority of the outstanding principal of the notes, be either payable on demand as of the closing of such change of control or Initial Public Offering (“IPO”) or convertible into shares of common stock immediately prior to such change of control transaction or IPO transaction at a price per share equal to the lesser of the per share value of the common stock as determined by the Company’s Board of Directors or the per share consideration to be received by the holders of the common stock in such change of control or IPO transaction. Based on the terms of the conversion, the holders may receive a discount, and the notes are considered to have a contingent beneficial conversion feature. If conversion of the debt occurs, the Company will recognize an expense related to the intrinsic value. The Company recorded $66,035 of accrued interest and has a total outstanding principal balance of $380,000 as of December 31, 2020.
Convertible Grid Notes [Member]
Convertible Notes Payable (Textual)
Principle amount				$ 125,000
Warrant purchase shares (in Shares)				750,000
Exercise price (in Dollars per share)				$ 0.80
Advance cash			$ 50,000

Notes Payable (Details)

Notes Payable (Details) - USD ($)	Nov. 13, 2020	Feb. 21, 2021	Dec. 28, 2020	Dec. 31, 2020	Oct. 23, 2019
Notes Payable (Details) [Line Items]
Loaned amount					$ 50,000
Description of non-convertible promissory note				The October Note bears interest at a fixed rate of 14% per annum, computed based on a 360-day year of twelve 30-day months, which interest will be payable quarterly until the maturity date.
Maturity date	Apr. 21, 2021
Interest expense			$ 11,000	$ 6,996
Outstanding principal balance				50,000
Accrued interest				1,356
Principal amount			$ 300,000
Aggregate purchase share (in Shares)			500,000
Commitment fee share (in Shares)			250,000
Additional commitment fee share (in Shares)			250,000
Net amount				265,000
Fixed interest percentage			12.00%
Installments amount			$ 56,000
Debt discount				300,000
Amortization of debt discount				2,466
Outstanding principal balance amount				300,000
Default interest rate			24.00%
Warrant exercise price (in Dollars per share)			$ 1.20
February 21, 2020 Note [Member]
Notes Payable (Details) [Line Items]
Outstanding principal balance				20,000
Accrued interest				$ 2,060
February 21, 2020 Note [Member] | Subsequent Event [Member]
Notes Payable (Details) [Line Items]
Loaned amount		$ 20,000
Description of non-convertible promissory note		The February Note bears interest at a fixed rate of 12% per annum, computed based on a 360-day year of twelve 30-day months, which interest will be payable quarterly until the maturity date.

Derivative Liabilities (Details

Derivative Liabilities (Details) - Schedule of financial liabilities measured at fair value on a recurring basis using significant unobservable inputs - (Level 3 [Member]	12 Months Ended
	Dec. 31, 2020USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance on December 31, 2019
Issuances to debt discount	1,330,752
Issuances to interest expense	2,513,323
Net extinguishment	79,621
Change in fair value of derivative liabilities	(801,801)
Change in fair value of warrant liabilities	(558,953)
Balance on December 31, 2020	$ 2,562,942

Derivative Liabilities (Detai_2

Derivative Liabilities (Details) - Schedule of derivative conversion features and warrant liabilities	12 Months Ended
	Dec. 31, 2020$ / shares
Derivative Liabilities (Details) - Schedule of derivative conversion features and warrant liabilities [Line Items]
Dividend yield	0.00%
Minimum [Member]
Derivative Liabilities (Details) - Schedule of derivative conversion features and warrant liabilities [Line Items]
Expected volatility	46.40%
Risk free interest rate	0.05%
Contractual terms (in years)	29 days
Conversion/Exercise price (in Dollars per share)	$ 0.80
Maximum [Member]
Derivative Liabilities (Details) - Schedule of derivative conversion features and warrant liabilities [Line Items]
Expected volatility	82.20%
Risk free interest rate	0.36%
Contractual terms (in years)	4 years 109 days
Conversion/Exercise price (in Dollars per share)	$ 1.28

Other Liabilities (Details)

Other Liabilities (Details)	1 Months Ended	12 Months Ended
	Jun. 30, 2017USD ($)	Dec. 31, 2016	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Other Liabilities (Textual)
Number of machines		2
Gain (loss) on sale of assets and asset impairment charges	$ 19,107
Other liabilities			$ 4,595	$ 6,377

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 28, 2020	Dec. 31, 2018
Related Party Transactions (Details) [Line Items]
Loan amount			$ 300,000
Mr. Sakharov [Member]
Related Party Transactions (Details) [Line Items]
Loan amount		$ 5,530		$ 50,000
Due to related parties	$ 55,530	55,530
Medical devices for resale and distribution cost	406,187	386,421
Expenses related to research and development cost	26,920	50,713
Sales and marketing costs	53,578	0
Affiliate of Boris Goldstein [Member]
Related Party Transactions (Details) [Line Items]
Loan amount		50,000
Due to related parties	50,000	50,000
Affiliate of Nickolay Kukekov [Member]
Related Party Transactions (Details) [Line Items]
Loan amount		217,000
Due to related parties	217,000	217,000
Board of Directors Chairman [Member] | Warehouse Space [Member]
Related Party Transactions (Details) [Line Items]
Related party transaction, rent payments	$ 0	$ 4,900

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Operating loss carryforwards	$ 9,252,000	$ 3,617,000
Description of operating loss carryforwards	future taxable income which will begin to expire in 2036 through 2040.

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of deferred tax assets and liabilities - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Schedule of deferred tax assets and liabilities [Abstract]
Net operating loss carry forwards	$ 2,596,740	$ 1,016,339
Stock based compensation	12,089	3,596
Depreciation	304	(22)
Valuation allowance	(2,609,133)	(1,019,913)
Net Deferred Tax Asset

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of reconciliation of the statutory federal income tax	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Schedule of reconciliation of the statutory federal income tax [Abstract]
Statutory federal tax rate	21.00%	21.00%
State taxes, net of federal benefit	9.39%	6.99%
Derivative revaluation	6.67%
Other	0.04%
Valuation allowance	(37.09%)	(27.70%)
Provision for income taxes	0.00%	0.30%

Leases (Details)

Leases (Details)	Jan. 02, 2020USD ($)	Jan. 02, 2020RUB (₽)	Jun. 02, 2019USD ($)	Jun. 02, 2019RUB (₽)	Dec. 01, 2018USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Leases (Details) [Line Items]
Lessee, operating lease, description					The lease was renewed on June 1, 2019 for an additional year ending May 31, 2020, for $3,171 per month.
Rent expense, monthly rent						$ 38,870	$ 85,771
Lease terms of office space						2 years
Weighted-average remaining lease term						1 year 244 days
Weighted-average remaining discount rate						12.00%
Operating lease						$ 1,968,169	1,072,196
Operating cash flows used in operating leases						18,272
Operating lease right of use assets						0
Minimum [Member]
Leases (Details) [Line Items]
Monthly rental expense						150
Maximum [Member]
Leases (Details) [Line Items]
Monthly rental expense						3,200
General and administrative expenses [Member]
Leases (Details) [Line Items]
Operating lease						$ 23,278	$ 0
12-Month Year Agreement [Member] | Third Party [Member]
Leases (Details) [Line Items]
Monthly rental expense	$ (240)	₽ 17,900
10-Month Year Agreement [Member] | Third Party [Member]
Leases (Details) [Line Items]
Monthly rental expense			$ (161)	₽ 12,000
Six Month Warehouse Rental Agreement [Member]
Leases (Details) [Line Items]
Monthly rental expense					$ 2,980

Leases (Details) - Schedule of

Leases (Details) - Schedule of maturity of lease liability	Dec. 31, 2020USD ($)
Schedule of maturity of lease liability [Abstract]
2021	$ 48,334
2022	32,699
Total undiscounted operating lease payments	81,033
Less: Imputed interest	(7,964)
Total operating lease liabilities	73,069
Less: Current portion of operating lease	(41,793)
Long-term portion of operating lease	$ 31,276

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of supplemental balance sheet information related to the lease - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Schedule of supplemental balance sheet information related to the lease [Abstract]
Operating lease right-of-use asset	$ 69,632
Lease liability, current portion	41,793
Lease liability, long-term	31,276
Total operating lease liability	$ 73,069
Weighted average remaining lease term (months)	20 years
Weighted average discount rate	12.00%

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - USD ($)	Nov. 13, 2020	Oct. 15, 2020	Sep. 22, 2020	Jun. 01, 2020	Apr. 21, 2020	Dec. 04, 2019	Oct. 07, 2019	Oct. 01, 2019	Sep. 01, 2019	Jan. 14, 2019	Sep. 21, 2018	Aug. 28, 2018	Aug. 08, 2018	Jan. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 30, 2018	Sep. 18, 2018
Stockholders' Deficit (Textual)
Preferred stock, authorized															10,000,000	10,000,000			10,000,000
Preferred stock, par value (in Dollars per share)															$ 0.001	$ 0.001
Common stock, authorized															200,000,000	200,000,000
Common stock, par value (in Dollars per share)															$ 0.001	$ 0.001
Common stock, shares outstanding															19,628,258	19,380,460
Number of share issued for services						75,000
Share price per share (in Dollars per share)						$ 0.12
Issued of Services (in Dollars)						$ 9,150									$ 207,732	$ 17,721
Warrant issued					1,500,000
Fixed exercise price (in Dollars per share)					$ 0.80
Dividend rate															0.00%
Minimum [Member]
Stockholders' Deficit (Textual)
Common stock, authorized																			50,000,000
Volatility rate															46.40%
Expected life (years)															29 days
Risk free interest rate															0.05%
Exercise price (in Dollars per share)															$ 0.80
Maximum [Member]
Stockholders' Deficit (Textual)
Common stock, authorized																			200,000,000
Volatility rate															82.20%
Expected life (years)															4 years 109 days
Risk free interest rate															0.36%
Exercise price (in Dollars per share)															$ 1.28
Securities Purchase Agreement [Member]
Stockholders' Deficit (Textual)
Warrant issued																100,000
Stock price per share (in Dollars per share)																$ 0.1208
Volatility rate																85.20%
Warrants exercise price (in Dollars per share)																$ 1.25
Triggering stock price percentage																100.00%
Securities Purchase Agreement [Member] | Minimum [Member]
Stockholders' Deficit (Textual)
Number of warrant reset															1,411,764	100,000
Fixed exercise price (in Dollars per share)															$ 1.20	$ 1
Securities Purchase Agreement [Member] | Maximum [Member]
Stockholders' Deficit (Textual)
Number of warrant reset															1,505,882	125,000
Fixed exercise price (in Dollars per share)															$ 1.28	$ 1.25
September 22, 2020 Securities Purchase Agreement [Member]
Stockholders' Deficit (Textual)
Warrant issued			1,411,764
Stock price per share (in Dollars per share)			$ 1.25
Volatility rate			84.00%
Triggering stock price percentage			100.00%
Fixed exercise price (in Dollars per share)			$ 1.28
Number of warrant expire			705,882
Warrant [Member]
Stockholders' Deficit (Textual)
Stock price per share (in Dollars per share)					$ 1
Fixed exercise price (in Dollars per share)															$ 0.97	$ 0.57	$ 0.40
Grid Warrants [Member]
Stockholders' Deficit (Textual)
Volatility rate					72.50%
Warrant exercise price (in Dollars per share)					$ 0.80
Three-Month Agreement [Member]
Stockholders' Deficit (Textual)
Number of share issued for services							22,500									4,000
Share price per share (in Dollars per share)							$ 0.12									$ 0.12
Issued of Services (in Dollars)							$ 2,745									$ 488
Advisor share of common stock							7,500	4,000
Six-Month Agreement [Member]
Stockholders' Deficit (Textual)
Issued of Services (in Dollars)	$ 100,000
Issue of shares for the services	100,000
Value of share issued for services (in Dollars)	$ 500
Compensation consultant in cash (in Dollars)	$ 6,000
Fair value per share (in Dollars per share)	$ 1
Consulting expenses (in Dollars)															$ 26,019
2018 Equity Incentive Plan [Member]
Stockholders' Deficit (Textual)
Issue of shares for the services											333,972
Common stock are reserved for issuance											3,500,000
Option outstanding											1,800,000
Option [Member]
Stockholders' Deficit (Textual)
Option, exercise price (in Dollars per share)															$ 0.75	$ 0.75
Remaining stock options will be amortized (in Dollars)															$ 28,230
Advisor [Member] | One Year Agreement [Member]
Stockholders' Deficit (Textual)
Value of share issued for services (in Dollars)									$ 2,000
Advisor [Member] | Four Month Agreement [Member]
Stockholders' Deficit (Textual)
Number of share issued for services									20,000
Advisor share of common stock				7,000					5,000
Number of common stock issued															28,000
Share price (in Dollars per share)									$ 0.10						$ 1.14
Value of share issued for services (in Dollars)															$ 32,025
Advisor [Member] | Issue Price One [Member] | One Year Agreement [Member]
Stockholders' Deficit (Textual)
Number of share issued for services															9,899	26,668
Share price per share (in Dollars per share)															$ 1.52
Issued of Services (in Dollars)															$ 15,000
Value of common stock issued (in Dollars)													$ 5,000
Number of common stock issued												6,667	6,667
Issue of shares for the services															9,899	26,668
Share price (in Dollars per share)													$ 0.08		$ 1.52	$ 0.08
Value of share issued for services (in Dollars)																$ 1,653
Value of share issued for services (in Dollars)															$ 15,000	1,653
One Year Agreement [Member] | Issue Price One [Member] | One Year Agreement [Member]
Stockholders' Deficit (Textual)
Value of common stock issued (in Dollars)												$ 5,000
Non-Executive Officer [Member]
Stockholders' Deficit (Textual)
Granted restricted shares		292,174
Grant fair value per share (in Dollars per share)		$ (1.67)
Amortized vesting period value (in Dollars)		$ 487,931
Stock-based compensation expenses (in Dollars)															45,706
Board of Directors [Member] | Option [Member]
Stockholders' Deficit (Textual)
Share price (in Dollars per share)										$ 0.042
Volatility rate										77.00%
Value of share issued for services										800,000
Expiration date										Jan. 14, 2029
Aggregate fair value of options (in Dollars)										$ 17,111
Expected life (years)										10 years
Risk free interest rate										2.71%
Dividend rate										0.00%
Exercise price (in Dollars per share)										$ 0.75
Stock option expense (in Dollars)															6,417	$ 10,432
Mr. Vadim Sakharov [Member]
Stockholders' Deficit (Textual)
Number of common stock issued										200,000
Boris Goldstein [Member] | Option [Member] | Employment Agreement [Member]
Stockholders' Deficit (Textual)
Share price (in Dollars per share)														$ 0.12
Amortized vesting period value (in Dollars)															$ 23,790
Volatility rate														76.00%
Description of options vesting period										The options have an exercise price of $0.75 per share which will vest over a 24-month period as follows: 25% (or 200,000 and 50,000, respectively) shall vest six months after the grant date with the remaining options will vest on a monthly basis at a rate of 1/24th per month.
Expiration date														Jan. 30, 2029
Aggregate fair value of options (in Dollars)														$ 51,757
Risk free interest rate														1.57%
Exercise price (in Dollars per share)														$ 0.75
Number of shares purchase for issuance of options														800,000
Option, exercise price (in Dollars per share)														$ 0.75
Jesse W. Crowne [Member] | Option [Member] | Employment Agreement [Member]
Stockholders' Deficit (Textual)
Expected life (years)														10 years

Stockholders' Deficit (Detail_2

Stockholders' Deficit (Details) - Schedule of warrant activity - Warrant [Member] - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Class of Warrant or Right [Line Items]
Warrant Number of Shares outstanding at beginning	502,250	402,250
Warrant Weighted Average Exercise Price outstanding at beginning	$ 0.57	$ 0.40
Warrant Weighted Average Remaining Contractual Term outstanding at beginning		4 years 262 days
Warrant Aggregate Intrinsic Value outstanding at beginning	$ 201,125
Granted Number of Shares	3,530,882	10,000
Granted Weighted Average Exercise Price	$ 1.02	$ 1.25
Granted Weighted Average Remaining Contractual Term	3 years 328 days	5 years
Granted Aggregate Intrinsic Value	$ 150,000
Forfeited Number of Shares
Forfeited Weighted Average Exercise Price
Forfeited Aggregate Intrinsic Value
Exercised Number of Shares
Exercised Weighted Average Exercise Price
Exercised Aggregate Intrinsic Value
Expired Number of Shares
Expired Weighted Average Exercise Price
Expired Aggregate Intrinsic Value
Warrant Number of Shares outstanding at ending	4,033,132	502,250
Warrant Weighted Average Exercise Price outstanding at ending	$ 0.97	$ 0.57
Warrant Weighted Average Remaining Contractual Term outstanding at ending	3 years 142 days	3 years 357 days
Warrant Aggregate Intrinsic Value outstanding at ending	$ 351,125	$ 201,125
Warrant Number of Shares exercisable at ending	2,533,132
Warrant Weighted Average Exercise Price exercisable at ending	$ 1.06
Warrant Weighted Average Remaining Contractual Term exercisable at ending	2 years 306 days
Warrant Aggregate Intrinsic Value exercisable at ending	$ 201,125

Stockholders' Deficit (Detail_3

Stockholders' Deficit (Details) - Schedule of option activity - Options [Member] - USD ($)	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
Stockholders' Deficit (Details) - Schedule of option activity [Line Items]
Option Number of Shares outstanding at beginning (in Shares)		1,000,000
Option Weighted Average Exercise Price outstanding at beginning		$ 0.75
Option Weighted Average Remaining Contractual Term outstanding at beginning
Option Aggregate Intrinsic Value outstanding at beginning (in Dollars)		$ 150,000
Granted Number of Shares (in Shares)		800,000	180,000
Granted Weighted Average Exercise Price		$ 0.75	$ 0.75
Granted Weighted Average Remaining Contractual Term		10 years	10 years
Granted Aggregate Intrinsic Value		$ 120,000
Forfeited Number of Shares (in Shares)			(800,000)
Forfeited Weighted Average Exercise Price
Forfeited Aggregate Intrinsic Value (in Dollars)
Exercised Number of Shares (in Shares)
Exercised Weighted Average Exercise Price
Exercised Aggregate Intrinsic Value (in Dollars)
Expired Number of Shares (in Shares)
Expired Weighted Average Exercise Price
Expired Aggregate Intrinsic Value (in Dollars)
Option Number of Shares outstanding at beginning (in Shares)		1,800,000	1,000,000
Option Weighted Average Exercise Price outstanding at ending		$ 0.75	$ 0.75
Option Weighted Average Remaining Contractual Term outstanding at ending		8 years 186 days	9 years 18 days
Option Aggregate Intrinsic Value outstanding at ending (in Dollars)		$ 270,000	$ 150,000
Option Number of Shares exercisable at ending (in Shares)		1,400,000
Option Weighted Average Exercise Price exercisable at ending		$ 0.75
Option Weighted Average Remaining Contractual Term exercisable at ending		8 years 124 days
Option Aggregate Intrinsic Value exercisable at ending (in Dollars)		$ 210,000

Concentrations (Details)

Concentrations (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Risks and Uncertainties [Abstract]
Percentage of medical devices	99.28%	99.84%

Commitments and Contingencies (

Commitments and Contingencies (Details) - One Year Agreement [Member]	Feb. 01, 2017
Investors [Member]
Commitments and Contingencies (Textual)
Percentage of warrant	10.00%
Retail [Member] | Third Party Member
Commitments and Contingencies (Textual)
Percentage of cash fee	10.00%
Percentage of expense allowance payable	3.00%

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Feb. 11, 2021	Feb. 08, 2021	Mar. 16, 2021	Jan. 26, 2021	Dec. 31, 2020	Apr. 21, 2020
Subsequent Events (Details) [Line Items]
Share offering, description					the Company is offering up to a maximum of 1,111,111 units, with each unit consisting of five shares of common stock, par value $0.001, and a warrant to purchase one share of common stock, par value $0.001, at an offering price of $9.00 per unit or $1.80 per share of common stock, for a maximum aggregate offering of $10,000,000.
Conversion price per share (in Dollars per share)					$ 1
Exercise price per share (in Dollars per share)						$ 0.80
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Maturity date		May 1, 2021
Number of common stock issued		50,000
Agreement amount (in Dollars)		$ 500,000
Interest rate		10.00%
Stock option share				16,779
Stock option agreements, description	On February 11, 2021, the Company granted certain employees options to purchase an aggregate number of 125,000 shares of common stock, exercisable at $1.50 per share which will vest over a 24-month period as follows: 25% shall vest six months after the grant date with the remaining options will vest on a monthly basis at a rate of 1/24th per month.
Outstanding principal amount (in Dollars)			$ 20,000
Outstanding interest amount (in Dollars)			$ 871
Applicable common share			27,828
Conversion price per share (in Dollars per share)			$ 0.75
Convertible Debt [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Conversion price per share (in Dollars per share)			$ 0.75
Number of warrant			166,667
Exercise price per share (in Dollars per share)			$ 0.75